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 OSW-1, a plant-derived cholestane glycoside, has been shown to exhibit broad-
spectrum antiviral activity by targeting oxysterol-binding protein (OSBP) and potent 
antiproliferative activity by targeting OSBP-related protein 4 (ORP4). In order to develop 
OSW-1 and OSW-1-derived compounds as potential antiviral or anticancer therapeutics, 
an understanding of OSW-1 structure-activity relationships (SAR) for binding to OSBP 
and ORP4 must be established. This SAR will allow for the identification of compounds 
with improved pharmacological properties and the development of selective OSBP- or 
ORP4-targeting compounds. To date, there are no reported protein structures of OSBP or 
ORP4, and the published research on OSW-1 only provides partial insight on the 
compound SAR.  The major goal of this research project is to purify and identify OSW-
1-related natural product compounds from Ornithogalum saundersiae bulbs. The new 
OSW-1-related compounds can then be subjected to biological testing, including binding 
to OSBP and ORP4, anticancer assays, and antiviral assays. Through the development of 
an efficient analytical method for the purification of natural products from Ornithogalum 
saundersiae, several OSW-1-related compounds, including newly discovered 
compounds, were purified and structurally characterized. Testing the isolated OSW-1-
related compounds for OSBP and ORP4 binding will provide further SAR understanding, 
and progressively guide the discovery and synthesis of new OSBP and ORP4 specific 
compounds for pre-clinical drug development as new antiviral and anticancer drugs. 
1 
Chapter I: Introduction and Background 
I.1 Overview of Naturally Occurring Small-Molecules in Drug Discovery 
 For millennia, natural products isolated from plants have provided health 
remedies.1 Natural product compounds form the basis of highly sophisticated systems of 
traditional medicine, including Traditional Chinese, African and Ayuverdic Medicine 
(India).2 In the modern scientific era, many pharmaceutical therapeutics are based on 
natural products (NPs), with the discovery of new natural products continuing to supply 
new therapeutic molecules.3 According to a recently published review, 1,881 new drugs 
were approved by the FDA and similar organizations between January 1981 and 
September 2019. Of these approved therapeutics, 1,394 were small molecule drugs, 
among which, 713 are unaltered NPs (N), NP-derived (NB and ND), or synthetic drugs 
with NP pharmacophores (S*or S*/NM). An additional 681 are total synthetic drugs or 
mimics of NPs (S or S/NM). The evolution of the source of small molecules has been 
followed over the last 38 years (Figure 1, adapted from Newmann and Cragg).4   
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 Several structurally diverse molecules isolated from plant extracts have proven 
their effectiveness. For example, Artemisinin, isolated from Chinese sweet wormwood 
(Artemisia annua) is an essential antimalarial drug.5 Paclitaxel, discovered from the bark 
of the Pacific yew tree (Taxus baccata) is a standard of care anticancer drug.6 
Galantamine is an alkaloid isolated from Snowdrops (Galanthus nivalis), which is used 













 The power of naturally occurring small-molecules lies in both their complexity, 
structural diversity, and disease-relevant biological activity.8 Even today, Nature remains 
our greatest source of molecular inspiration, and new natural product molecules continue 
to be discovered in plants.9 One specific family of bioactive NPs isolated from plants with 
potential therapeutic applications are the cholestane glycosides. 
 
 
Figure 2. Structurally diverse bioactive natural products 
3 
I.2 Saponins and Cholestane Glycosides  
 Saponins are a class of naturally occurring bioorganic compounds found in 
particular abundance in the plant kingdom. More specifically, they are glycosides 
described by the soap-like foaming (from Latin sapo meaning soap).10 Structurally, these 
compounds have at least one glycosidic linkage between a hydrophobic aglycone 
(steroidal-C27 or triterpenoid-C30 skeleton) and varying numbers of hydrophilic sugar 
moieties (Figure 3).10–13 
Individual saponins display a range of exceptional medicinal properties and biological 
activities such as hemolytic, molluscicidal, anti-inflammatory, antifungal, antibacterial, 
antiviral, anticancer and cytotoxicity.11 These properties represent the increasing 
importance of saponins in prospective therapeutic uses.14 The discovery of Digitalis and 
Digoxin is a good example. These two steroidal saponins isolated from Foxglove 
(Digitalis purpurea) are cardiac glycosides used in the treatment of certain heart 
conditions such as congestive heart failure and heart rhythm problems.15 
Figure 3. General saponin structure 
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 Likewise, the Ornithogalum plant genus (Figure 4) has drawn considerable 
attention over the past 15 years due to its production of steroidal saponins.13 Although 
most Ornithogalum species do not exhibit medicinal properties, and some are even 
poisonous,16 Ornithogalum bulbs produce a number of cholestane glycosides with 
promising biological activity, especially selective activity against malignant cancer cells 
versus  non-transformed cells17). 
Despite their general structure similarity, these natural compounds are different in their 




Figure 4. Steroidal saponin subfamilies from the Ornithogalum Genus (A) and 




I.3 The OSW-1 Natural Product  
 The Ornithogalum saundersiae flowering plant, also called the African Lily, is a 
perennial garden plant species native to the African Drakensberg Mountains, located in 
the Highveld region of South Africa and Swaziland.17,30 In 1992, the Sashida group from 
the Tokyo College of Pharmacy disclosed the discovery and structural characterization 
of a group of cholestane glycosides isolated from a methanolic extract of O. saundersiae 
bulbs. The main component of this mixture was termed OSW-1 (Figure 5).19 
Upon isolation, OSW-1 was identified as a micromolar inhibitor (IC50 = 50 µM) of cyclic 
adenosine monophosphate (cAMP) phosphodiesterase (PDE).17,19 Cyclic AMP is a 
nucleotide, which acts as a key second messenger in many signal transduction pathways 
involved in regulating various cellular functions, including cell growth, differentiation, 
Figure 5. First group of cholestane glycosides (right) isolated from Ornithogalum 
saundersiae plant (left) 
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gene transcription and protein expression.31 A PDE is an enzyme that degrades cAMP, 
thus influencing a vast array of pharmacological processes (e.g, pro-inflammatory 
mediator production, ion channel function, muscle contraction, differentiation, 
apoptosis). Inhibition of this enzyme causes cAMP increase, thus for example preventing 
heart failure or antagonizing malignant tumors in myeloid and lymphoid tissue.32  
 Five years later, OSW-1 was identified as the main cytotoxic compound contained 
in the bulbs, due to its exceptional potent cytotoxic activity against various malignant 
tumor cells, including HL-60 human promyelocytic leukemia cells.33 In comparison with 
clinically applied anticancer agents, such as etoposide (IC50 = 25 nM), Adriamycin (IC50 
= 7.2 nM) and methotrexate (IC50 = 12 nM), OSW-1 strongly suppresses HL-60 cell 
proliferation with an IC50 value of approximately 0.25 nM.
28,33 Moreover, OSW-1 
demonstrated exceedingly potent activities when tested in the National Cancer Institute 
60 cancer cell lines (NCI-60), with the mean growth inhibition (GI50) of 0.78 nM, which 
is 10-100 times more potent than cisplatin, Taxol and mitomycin C.33 
 The OSW-1 compound has received great scientific attention because of its potent 
cytotoxic activities against various cultured tumor cell lines and cell growth inhibitory 
activities against experimental animal tumors.17 These in vitro cytotoxic and in vivo 
antitumor screenings of OSW-1 have revealed that it is a possible novel anticancer drug 
candidate.17,34 However, at that time, the lack of identification of the cellular targets and 
mechanism of action of OSW-1 limited its anticancer drug development.35–47 
I.4 OSW-1’s Cellular Targets: The OSBP and ORP Protein Family  
 In 2011, Burgett et al. identified oxysterol-binding protein (OSBP) and OSBP-
related protein 4 (ORP4) as the cellular targets of OSW-1.40  Subsequent to that discovery, 
7 
ORP4 has been recognized as a driver of cancer cell proliferation, including in patient 
isolated leukemias.40,44,45 Unexpectedly, OSBP was recently discovered to be essential 
for RNA viral replication, and OSW-1 was reported to potently inhibit RNA viral 
replication by targeting OSBP.48,49 
 Oxysterol-binding protein (OSBP) and OSBP-related-proteins (ORPs) constitute 
a conserved family of eukaryotic proteins, from yeast to humans.50–56  The OSBP/ORPs 
are involved in diverse cellular activities, including regulation of signaling pathways, 
lipid transport between organelles and lipid metabolism. The human OSBP/ORP family 
consists of 12 proteins (splicing generates 15 proteins), which can be subdivided into 6 
subfamilies based on gene organization and amino acid homology (Figure 6). All 
members of this protein family possess a conserved sterol- or ligand-binding domain, 
named the OSBP-related domain (ORD).50–56 The ORD contains conserved signature 
fingerprint region (EQVSHHPP). Outside of the ORD, several other regulatory domains 
are present in individual OSBP/ORPs. The N-terminal pleckstrin homology (PH) domain 
recognizes phosphatidylinositol phosphates (PIPs) with varying degrees of  affinity.51,57 
The “two phenylalanines in an acidic tract” (FFAT) sequence motif allows for proteins 
to associate with the endoplasmic reticulum (ER) by binding vesical associate proteins 
(VAP).53,58 The ankyrin repeats (ANK) allow ORP1L to associate with late endosomes.59 
Instead of FFAT motifs, ORP5 and ORP8 possess transmembrane (TM) domains that 
anchor the protein to membranes. 60 Additionally, some OSBP/ORP proteins have both 
short (S) variants, which lack the N-terminal PH domain and others present in the long 
(L) variants. The ORP short and long variants arise transcriptional initiation at different 
start-sides of the gene. 54  
8 
Among this protein family, two members of subfamily I, OSBP and ORP4L, have drawn 
particular interest for the reasons stated above. These proteins share similar features such 
as the PH and FFAT domains and 68% identity in the ORD, resulting in 59% overall 
sequence homology (Figure 7).51 However, OSBP and ORP4L have significantly 
different biological activities.40,61   
Figure 6. Domain homology diagrams of the human ORPs superfamily. Graphs 
were generated using DOG 2.0 software 
9 
I.4.1 OSBP and ORP4 as Druggable Targets   
 OSBP was originally discovered due to its ability to bind oxysterols.62 These 
steroidal compounds are oxygenated derivatives of cholesterol involved in various 
cellular signaling responses.50,53,56,63 Disruption of oxysterol activity can promote 
malignant cell proliferation.50,53,56,63 OSBP particularly binds 25-hydroxycholesterol (25-
OHC) with high affinity (KD = 22 ± 5 nM)
64 in comparison to cholesterol (KD ≈ 173 
nM)65,66. Likewise, ORP4L binds to 25-OHC with similar affinity (KD = 17 nM)
40 and to 
cholesterol at lower affinity (KD = 63 nM).
42,62,67 There are no protein structures of OSBP 
or ORP4, making ligand binding on the molecular level unclear. There are only protein 
structures of Saccharomyces cerevisiae yeast OSBP homologs (i.e., Osh proteins), which 
share approximately 55% overall sequence homology.56,59,68,69 Im et al. reported the first 
structure of Osh4 co-crystalized with several oxysterols including 25-OHC.56,59,68 
According to this co-crystal structure, the ligand-binding pocket contains a hydrophobic 
tunnel and a flexible N-terminal lid capable of shielding the bound ligand sterol from the 
aqueous environment.70 After lipid transport, the lid opens and has a flat surface allowing 
Figure 7. OSBP and ORP4L domain homology diagrams. Graphs were generated 
using DOG 2.0 software 
 
10 
for contact with the cell membrane and possible sterol injection into the membrane 
(Figure 8A).70 The C3-hydroxyl group of 25-OHC forms direct hydrogen bonding with 
Gln96 residue and water-mediated hydrogen bonds to a polar cluster of amino acids at 
the bottom of the ligand binding pocket. Likewise,C25-hydroxyl group interacts with a 
water molecule that mediates interactions with Leu24, Leu27, Lys109 and Ala29 residues 
in the lid putative region (Figure 8B).70–73 
 
  
 In addition to oxysterols, Burgett et al. were able to demonstrate, through affinity 
purification and proteomic analysis, that OSBP and ORP4L are the specific cellular 
targets of a group of structurally diverse naturally-occurring small molecules, including 
OSW-1, cephalostatin74, ritterazine B74,75, schweinfurthin A76 and stellettin E77 (Figure 
9). These natural products have been named the ORPphilins, based on their ability to 
interact with OSBP and ORPs.40 
Figure 8. (A) Structure of Osh4 co-crystallized with 25-OHC. Protein backbones and 
sidechains are colored according to residue sequence identity, from blue (N-terminal), to 
red (C-terminal). (B) 25-OHC interacting with tunnel entrance and N-terminal lid 
region residues. 25-OHC is highlighted in purple and residues that interact with 25-OHC 
are highlighted in green. Figures were generated using RCSB Protein Data Bank. 
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 As mentioned above, 25-OHC is a high affinity ligand of OSBP and ORP4L. 
Therefore, to assess each ORPphilin’s OSBP and ORP4L binding affinity, competitive 
binding assays were carried out with [3H]25-OHC. Results for OSW-1, cephalostatin, 
ritterazine B and schweinfurthin A are summarized in Table 1. Ritterazine B binds to 
OSBP with higher affinity than ORP4 in the 25-OHC competitive binding assay. 
Stellettin E was not available for testing and putatively assigned as an ORPphilin based 
on similar antiproliferative profiles to the ORPphilin.40  
 25-OHC Cephalostatin OSW-1 Ritterazine B Schweinfurthin A 
OSBP 32 ± 14 39 ± 10 26 ± 9 28 ± 4 68 ± 23 
ORP4L 54 ± 23 78 ± 15 54 ± 11 >350 2,600 ± 570 
Table 1. ORPphilins inhibitory constant (Ki) values (nM) compared to 25-OHC 
Figure 9. Chemical structures of ORPphillins 
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These results indicate that the ORPphilins indeed bind to both OSBP and ORP4L with 
high affinity.40 Schweinfurthin A and Ritterazine B are outliers in that their affinity for 
ORP4L was considerably lower than their affinity for OSBP.40 
I.4.2 Potential Anticancer Drug Development by targeting ORP4L 
 ORP4L was demonstrated to be overexpressed in cancer and to drive cancer 
proliferation. ORP4L is reported to be essential for mitochondrial bioenergetics in T-cell 
acute lymphoblastic leukemia (T-ALL).44,45,78 The protein is proposed to function as a 
scaffold for inositol triphosphate (IP3) signaling, which ultimately results in calcium 
(Ca2+) uptake into the mitochondria.44,45,78 More precisely, ORP4L assembles CD3ε, 
Gαq/11 and PLCβ3 into a complex that activates PLCβ3.
44,45,78 PLCβ3 catalyzes IP3 
production in T-ALL, as opposed to PLCγ1 in normal T-cells, allowing Ca2+ release from 
the ER and thus increased oxidative phosphorylation. (Figure 10).36,41,42,44,47  
Figure 10. ORP4L mediates G protein-coupled ligand-induced PLCβ3 activation, 
resulting in an increase of mitochondrial respiration for cell survival 
13 
Inhibition of ORP4L expression in T-ALL cells prevents malignant cell proliferation and 
leads to apoptosis.45 Hence, ORP4L can serve as a precision cancer therapeutic target.79   
I.4.3 Potential Antiviral Drug Development by targeting OSBP 
 In contrast with ORP4L, OSBP is present in all human tissues.53,80,81 It is localized 
in the cytosol at the Golgi-ER interface, and recently, OSBP has been reported to play a 
pivotal role in PI(4)P and cholesterol counterflow transport between the ER and 
Golgi.53,80,81 OSBP is able to contact both the ER membrane with its FFAT domain and 
the Golgi membranes with its PH domain.81 Tethered by the PH and FFAT domains, the 
ORD is able to transfer cholesterol from the ER to the Golgi, and back transfer PI(4)P 
from the Golgi to the ER. PI(4)P is then hydrolyzed by the ER protein Sac1 to provide 
energy which drives the sterol transfer (Figure 11).81 In addition to these cellular 
activities, OSBP is implicated in multiple human diseases, including neurological 
disorders, such as amyotrophic lateral sclerosis (ALS), as well as viral infection, 
replication and release51,53,56,78,82. Hence, OSBP-targeting compounds can lead to the 
development of anti-viral therapeutics.49,64,83 
  
Figure 11. OSBP-mediated back transfer of PI(4)P coordinates the transfer of  
lipid species at the ER-Golgi interface (reproduced from Mesmin et al. with 
permission)81 
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 As mentioned above, OSBP is implicated as an essential host protein in a wide 
variety of RNA viral infections, namely Hepatitis C (HCV), Enteroviruses—a family of 
positive-strand RNA viruses implicated in a panel of diseases) — Zika virus, Dengue 
fever virus, and encephalomyocarditis (EMCV).84–89 Currently, there are no direct 
antiviral treatments available for  any of these viral pathogens, limiting the clinical 
intervention to supportive therapy.90 The clear need to develop effective therapeutics for 
these serious RNA viral pathogens has driven substantial progress in identifying 
candidate targets for anti-viral drugs.91 In that respect, compounds including OSW-1, 
itraconazole (ITZ), T-001270HEV2 (THEV), and TTP-8307 (TTP) demonstrate potent 
anti-viral activity through targeting OSBP (Figure 12).48,49,64,83,92  
  OSBP is postulated to play an essential role in the formation of viral replication 
organelles (ROs).83 The ROs are membrane wrapped structures that allow viral 
components to hide from the cellular anti-viral innate immunity factors.83 For many 
viruses, the viral genome is replicated by assemblies of viral and host proteins located in 
Figure 12. Structurally diverse anti-viral small molecules 
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ROs formed at ER-Golgi interface.83 RNA viral replication is particularly associated with 
dysregulation of lipid homeostasis, in which OSBP plays a role. Through viral 
recruitment of the type III phosphatidylinositol-4-kinase β (PI4KIIIβ) enzyme, PI4P is 
generated at ROs, and in the case of Enteroviruses, the cholesterol shuttling ability of 
OSBP is hijacked to make the viral ROs, in order to carry out efficient replication within 
the host cell.53,93,94 Strating et al. reported that ITZ, an anti-fungal agent, perturbates this 
process by binding OSBP, which results in an arrest of cholesterol shuttling between 













  Most recently, the Burgett Research group investigated the effects of the 
structurally-diverse antiviral small molecule compounds (Figure 12) and their ability to 
interact with and modulate OSBP’s cellular activity through different mechanisms. 
Figure 13. Enterovirus replication inhibition mechanism 
of action (reproduced from Strating et al. with permission)83 
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Interestingly, ITZ and TTP, which are reported to target OSBP, do not inhibit the binding 
of 25-OHC to OSBP, indicating that these compounds bind OSBP at a different ligand 
binding site.64 Both THEV and OSW-1 inhibit binding of 25-OHC with nanomolar Ki 
values. Moreover, OSW-1 is the only compound among all that causes a ~90% reduction 
in cellular OSBP levels and induces a prophylactic antiviral response in cells.95 Although 
the exact mechanism of the OSW-1-induced OSBP repression has not been identified yet, 
OSW-1 is the example of a potential broad spectrum prophylactic anti-viral through 
targeting a human protein.64,95  
 The drug development potential of OSW-1 has drawn particular interest due to its  
exceptional antiproliferative and antiviral activities through targeting ORP4L and OSBP 
respectively.35–37,40,64 However, as shown in Table 1, the OSW-1 compound binds to both 
proteins with comparable affinity, which could result in unwanted side effects.40 There 
are currently no direct experimental results characterizing the binding of OSW-1 to 
OSBP, ORP4L or any other OSBP/ORP protein. Computational models have docked 
OSW-1 on to the OSBP and ORP4 homology models built off the Osh protein structures, 
but these models are of unclear value due to the lack of protein structural and functional 
information. This renders the understanding of OSW-1’s interaction within the binding 
pocket challenging. Furthermore, the OSW-1 compound has been extensively studied for 
its anti-proliferative properties by testing related analogs on various cancer cell lines 
(discussed in Section I.5), but very few binding activities have been reported.51,54–56 
Identifying how it binds to OSBP/ORP4L could allow us to supplement current SAR 
models and efficiently modulate its components, with the ultimate goal of novel small-
molecule precision therapeutic development. 
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I.5 Reported Biological Activities of OSW-1-Related Compounds  
 As stated previously, OSW-1 has mainly been studied for its anti-cancer activity.  
Cytotoxic (or cell-killing) agents capable of directly destroying tumor cells constitute a 
vital treatment for cancer.96 Despite meaningful improvements in cancer drug 
development and biomedical research, most anti-cancer agents remain toxic to normal 
cells.97 Cytotoxic chemotherapeutic agents have severe side effects, and the therapeutic 
administration of these drugs is often limited by the side effects. Simultaneous resistance 
of tumor cells to cytotoxic drugs is also a major limitation. Multi-drug resistant (MDR) 
cells exhibit reduced accumulation of drugs, altered expression and/or activity of certain 
cellular proteins, physiological changes that alter the intracellular milieu, and a high rate 
of mutation that decreases the affinity of receptors/enzymes for the drug.98  The failure 
of existing chemotherapy drugs to provide an effective treatment with acceptable side 
effects fuels the pursuit of new cancer-selective agents functioning through novel modes 
of action. OSW-1, through targeting ORP4L, has shown promising preclinical anticancer 
efficacy and cancer selectivity.17,33,34 As a result, between 1992 and 2019, a multitude of  
analogs have been tested in vitro for their cytotoxic activities on various cancer cell 
lines.17,19,20,22–25,27,29,33,99–101 These experiments provide a starting point for defining 
OSW-1’s SAR. As with any cytotoxic compounds, the cytotoxicity is cell line-dependent. 
All compounds with IC50 values greater than 10,000 nM are considered inactive.
10,12-25  
I.5.1 Biological Activities of Natural OSW-1 Analogs 




 The Structure A class (Figure 14A) is related to OSW-1, as the 3β,16β,17α 
dihydroxyl steroid core is largely unmodified.17,19,28,29,33 Compounds with Structure A 
are either monodesmosidic or bisdesmosidic, depending on the sugar fraction having one 
or two attachment points respectively. Natural products with Structure B (Figure 14B) 
all possess a fused oxygen-containing E-ring instead of an aliphatic side chain. 
Interestingly, the C-21 methyl is retained with identical stereochemistry to OSW-1. 
Moreover, all compounds with Structure B are monodesmosidic, as the saccharide 
component (mainly β-D-glucopyranoside) is linked to the C-1 or C-3 position of the 
 
Figure 14. Isolated cholestane glycosides (1-52) structural classes (A and B) 
Structure B Structure A 
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steroidal core .17,22,100,101  The isolated O. saundersiae natural products were tested for 
antiproliferative activity on various cancer cell lines, including HL-60 and A549 (Figure 
15).17,19,20,22–25,27,29,33,99–101 Detailed structures of  all OSW-1 natural analogs and their 





 Substituents IC50 values (nM) 
Compounds R1 R2 R3 HL-60 A549 
1 H H H 3.4 ± 0.076 98 ± 8.0 
2 (OSW-1) H PMBz H 0.19 ±0.0026 1.7 ± 005 
3 H DMBz H 0.077 ±0.0070 0.68 ±0.057 
4 H (E)-CNM H 0.24 NT 
5 glc PMBz H 0.12 NT 
6 glc (E)-CNM H 16 NT 
7 H DMBz glc 14 NT 
8 H TMBz glc 0.20 ± 0.0074 3.6 ± 0.37 
9 H PHBz H 0.55 ± 0.013 6.2 ± 0.10 
10 H TMBz H 3.4 ± 0.076 98 ± 8.0 







 Substituents IC50 values (nM) 
Compounds R1 R2 R3 R4 HL-60 A549 
16 H OH H Ac 0.99 NT 
19 H OH H TMBz 50 ± 10 270 ± 40 
20 H OH H PMBz 60 ± 2 370 ± 90 
 
Figure 15. Cytotoxic Activities of a selection of OSW-1 analogs with Structure A 
tested against HL-60 and A549 cancer cell lines. NT: not tested 
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The most cytotoxic analogs were the ones that retained the OSW-1 structure (Structure 
A, Figure 14) with IC50 values ranging from 0.077 nM to 98 nM, but none were more 
potent than OSW-1 (Figure 15). Interestingly, compound 4 (Figure 15) comprised of an 
(E)-cinnamoyl group instead of a benzoyl group at the C-2 position of the D-
xylopyranoside is almost as potent as OSW-1 (0.077 nM). Cholestane rhamnosides (16, 
19 and 20, Figure 15) were less potent. The hydrophilic substituents of the hydroxyl 
group at C-11 and/or the glucosyl group at C-3 in the steroidal frame reduced the 
cytotoxicity of these compounds and rendered them inactive (Appendix A, B). 
Compounds with Structure A lacking the C-22 ketone (33-36, Figure 14) showed no 
activity (Appendix A,B). Moreover, most analogs with Structure B (37-52, Figure 14) 
were somewhat active against HL-60 cell lines (Appendix C, D), although the deacyl 




 Substituents IC50 values (nM) 
Compounds R1 R2 R3 HL-60 
39 CHO glc2 → 1rha H inactive 
40 CHO rha  H inactive 
41 CHO rha4 → PHBz H 21 
42 CHO rha4 → PMBz H 19 
43 CH2OH rha4 → PHBz H 63 
44 CH2OH rha4 → PMBz H 52 
45 CH2OH rha4 → PHBz OH 37 ± 4.4 
46 CH2OH rha4 → PMBz OH 90 ± 14 
 
 Substituents IC50 values (nM) 
Compounds R HL-60 
37 glc2 → 1rha 1,800 
38 4rha → PMBz 9.2 





rha 58 ± 2.0 900 ± 11
51 OH rha
4
 →  PHBz 67 ± 0.23 850 ± 15
52 H rha
4 
→ PMBz 170 ± 5.1 5,500 ± 170
Substituents IC50 values (nM)
Figure 16. Cytotoxic Activities of a selection of OSW-1 analogs with Structure B 
tested against HL-60 and A549 cancer cell lines. 
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 More recently, Chen et al. reported the isolation of 15 new compounds from O. 
saundersiae bulbs (Figure 17, nomenclature was adapted from Chen et al.).21,103 These 
new oxygenated cholestane glycosides were named osaundersiosides. Interestingly, all 
the compounds had structures similar to Structures A and B (Figure 14), but are mainly 
different in the positions of the various substituents. 21,103 These compounds (53-67, 
Figure 17) were tested on five different cancer cell lines (A549, BGC-823, HepG2, HCT-
116, MCF-7) and were surprisingly found to all be inactive (Appendix E).21,103 
Figure 17. New inactive cholestane glycosides isolated from O. saundersiae bulbs 
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I.5.2 Biological Activities of Synthetic OSW-1 Analogs 
 Several OSW-1 total syntheses have been reported.104–106 An efficient total 
synthesis of a natural product compound can supply significant quantities of a compound 
and provided for the generations of analog compounds.30,107–123 The first total synthesis 
of OSW-1 was accomplished seven years after its discovery by the Yu group, in 27 steps 
with the longest linear sequence being 14 steps, and in 6% overall yield.104 Most recently, 
the Guo group was able to scale up the synthesis and afford the OSW-1 compound in 10 
steps with  an overall yield of 6.4%.106 Likewise, many synthetic analogs have been 
developed to access new OSW-1-congeners for SAR studies. Synthetic OSW-1 analogs 
either had a modified steroidal nucleus, a different side chain and/or an altered 
disaccharide moiety.30,107–123 These OSW-1-related compounds were also tested for 
biological activity.17,117,120 Detailed structures of  all OSW-1 synthetic analogs and their 
cytotoxic activities can be found in Appendix F-I.  
 There is an overall lack of consistency in biological testing, which renders 
comparison challenging. However, in summary, based on the reported results, it seems 
that extension of the aliphatic side chain or changes to C22 functional groups (ester, 
amide, thioester, ether, unfunctionalized C-22 position) leads to mixed results, with 
potency or inactivity depending on the cancer cell line.111,116,119,122 Conversely, shortening 
of the aliphatic side chain significantly decreases potency (Appendix G, H).111,116,119,122 
 The disaccharide moiety can also be modulated to understand its utility within the 
molecule. Most recently, Sakurai et al. reported that the disaccharide component was 
found as a structural scaffold required for biologically functionalities.17,124 In other terms, 
the arabinose and xylose moieties are hypothesized to serve as a spacer for the extension 
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of the critical benzoate moiety to the desired position near the side chain component, 
while the C-17 hydroxyl, C-22 ketone and the acetate moiety on the arabinose participate 
in a hydrogen-bonding network to provide the optimal conformation of the OSW-1 
molecule (Figure 18).17,124  
 Recently, the most promising results related to OSW-1 anti-cancer research 
involves the development of an analog named LYZ-81 (107, Figure 19) by the Lei group. 
When tested against mice leukemia cells in vitro and in vivo, both compounds were well 
tolerated, but LYZ-81 interestingly shows increased efficacy in comparison to OSW-
1.109,113 Most importantly, LYZ-81 differs from OSW-1 by the presence of a hydroxyl 
group at the C-26 position and the absence of one at the C-17 position. This compound 
selectively targets ORP4L with high affinity (KD= 1.05 ± 0.26 nM) over OSBP (KD = 
5,900 ± 1,860 nM), which suggests the possibility to develop new OSW-1-derived 
compounds that selectively bind to either OSBP or ORP4L.109,113 
 
Figure 18. Hypothesized model of OSW-1’s hydrogen bonding network. Hydrogen 
bonds are shown in blue. Figure was adapted from Cori Malinky’s dissertation 
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 IC50 values (nM) KD values (nM) 
Compounds Leukemia Stem Cells (LSCs) OSBP ORP4L 
OSW-1 0.152 1.49 ± 0.26 0.85 ± 0.17 
LYZ-81 3.27 5,900 ± 1,860 1.05 ± 0.24 
 
Figure 19. Comparison of OSW-1 and LYZ-81 cytotoxic activities against 
Leukemia Stem Cells (LSCs) and binding affinities to OSBP and ORP4L109,113 
 The discovery and synthesis of all these diverse O. saundersiae cholestane 
glycosides provides important information to determine the SAR of OSW-1. The OSW-
1-related compounds, either synthesized or isolated from the natural source, have 
provided valuable  insights for the derivatization of OSW-1 to the potential development 
of antiviral and anticancer agents through targeting the OSBP and ORP4 proteins.   
I.5.3 Current OSW-1 SAR  
 Because of OSW-1’s biomedical interest, several groups have achieved its total 
synthesis and a number of its analogs have been tested.28-40,42–45,65,99,100 These analogs can 
contribute to deciphering OSW-1’s SAR, which is basis to explore more potent 
analogs.28-40,42–45,65,99,100 In 2013, based on all the reported cytotoxic activities, Tang et al. 
proposed a model of OSW-1’s SAR (Figure 20).17 
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Based on literature, both acyl groups on the disaccharide are critical for the bioactivity.17 
The A,B-ring system can be modified without significant loss of activity. Moreover, it 
has been determined that the disaccharide component is essential for the anti-cancer 
activity.17,124 Homology modeling and molecular docking studies suggest that the sugar 
does not directly bind to the protein, but rather acts as a spacer unit that gives the correct 
conformation to OSW-1 via hydrogen bonding, forming a stable complex within the 
binding pocket, and allowing OSW-1 to interact with the protein.17,124  
 For the past three decades, many studies related to OSW-1’s anti-proliferative 
activity have been carried out, but nothing has been reported for binding activities. It has 
been hypothesized that the side chain is essential for binding activity, but more SAR 
studies are needed to confirm this hypothesis. As mentioned previously, the way OSW-1 
binds to OSBP and ORP4 is not necessarily understood. Moreover, the protein structures 
remain unsolved, which renders the understanding of these binding interactions unclear. 
Determining what is responsible for the binding of OSW-1 at the molecular level will 
allow for the development of selective OSBP-targeting anti-viral drugs, and likewise, 
Figure 20. Most recent OSW-1 SAR model 
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ORP4-targeting precision therapeutics. The best way of doing that is by modulating 
specific components of the molecule and developing concise structure activity 
relationships. In order to supplement the current SAR model, more analogs are needed, 
and two approaches are considered to obtain them: synthesis, which can be very time-
consuming, especially for these complex scaffolds, or direct isolation from the plant.  
Testing of these analogs will allow to further supplement OSW-1’s SAR and understand 
how it binds to the proteins to ultimately develop potential selective high affinity antiviral 
















Chapter II: Isolation, Characterization and Evaluation of OSW-1 
Related Compounds 
II.1 Abstract 
 The OSW-1 natural product demonstrates antiviral activity through interacting 
with OSBP and anti-proliferative activity through interacting with ORP4L. However, 
OSW-1 binds to both proteins with comparable affinities. As a result, OSW-1 itself 
cannot be developed into a drug, as unwanted side effects may arise. To this day, the way 
OSW-1 binds to OSBP and ORP4L remains unknown. Although many OSW-1-related 
compounds have been isolated from O. saundersiae bulbs and evaluated for their 
cytotoxic activity, the binding affinities of these related compounds have not been tested. 
This is essential to further supplement SAR studies and develop a complete OSW-1 SAR 
model. Obtaining natural OSW-1-derived products is the most direct source of 
compounds to study how OSW-1 interacts with its cellular targets OSBP and ORP4L; the 
chemical synthesis of the diverse and structurally complex OSW-1 compounds is  much 
more demanding. Herein, a novel and efficient isolation procedure to isolate many OSW-
1 natural product compounds, including new compounds, from O. saundersiae bulbs is 
reported. The procedure is different from previously reported methods by the use of 
alternative extraction and purification methods and especially by the development of a 
novel detailed analytical method allowing the isolation of multiple compounds in a 
reproducible manner. A diverse library of known and newly discovered natural products 
are structurally characterized, and the future testing of these OSW-1-related compounds 
will provide important SAR understanding of OSBP and ORP4L compound binding and 
potential drug development.  
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II.2 Introduction 
 Natural products and their derivatives provide an unprecedented range of  
chemical structure diversity.126 Naturally-occurring small molecules have been 
recognized as an outstanding source of chemical probes used to interrogate biological 
functions, and further serve as therapeutic leads in drug discovery and development.127 
Due to an increasing demand for chemical diversity, seeking therapeutic drugs from 
natural products has continued to increase.128 
Phytochemical analysis of Ornithogalum saundersiae bulbs has yielded a 
significant amount of potent cytotoxic cholestane glycosides, including OSW-1.10,12-27 
Bioactive cholestane glycosides derived from Ornithogalum saundersiae bulbs have been 
discovered through a series of extraction, isolation and purification processes.17,19,28 The 
approach to isolate natural products starts with identification, collection and preparation 
of the biological material (Figure 21).  
  
Organic solvent extraction is an essential step in the isolation of natural products.128 
Several extraction methods exist, including maceration, percolation, decoction, infusion, 













Figure 21. General approaches in extraction of bioactive compounds from plants 
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Method Solvent Time Specifics 
Maceration 
Water, aqueous and 
organic solvents 
Long 
Solid plant material is placed in a stoppered 
container with the whole of the solvent and 
allowed to stand for a period of 3 to 7 days 
with frequent agitation, until soluble matter is 
dissolved. 
Percolation 
Water, aqueous and 
organic solvents 
Long 
Process of extracting soluble constituents of a 
powdered substance by slow passage of a 
liquid through it. 
Decoction Water Moderate 
Powdered plant material is boiled in a 
specified volume of water for a defined time; 
it is then cooled and strained or filtered. 
Infusion  Water Short 
Plant material is macerated for a short period 




Moderate Plant material is treated with boiling solvent. 
Soxhlet Extraction Organic solvents Long 
Continuous extraction of plant material by a 
hot solvent. 
Hydro distillation Water Long 
Plant material is soaked in boiling water. This 
is the widely used process for isolation of 
essential oils. 
Table 2. Brief summary of various extraction methods for natural products 
Determination of total plant contents can then be proceeded via individual extraction in a 
solvent (e.g, n-butanol), or by consecutive extraction in solvents of  increasing polarity 
(e.g, n-hexane, petroleum ether, chloroform, ethyl acetate, ethanol, acetone and water).130 
Pure bioactive compounds are further obtained by separation and purification methods 
such as Thin Layer Chromatography (TLC), Column Chromatography (CC) or 
HPLC.127,131 Due to a combination of various types of phytochemicals that differ in 
composition and polarities, their separation and purification remain key challenges in 
natural product drug discovery and development.129 The chemical structures of the pure 
compounds are then elucidated using a wide range of spectroscopic techniques, including 
UV, IR, NMR and MS, prior to biological evaluation.127,129,131 
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II.3 Results and Discussion 
II.3.1 Extraction 
 The discovery of OSW-1 and other OSW-1-related cytotoxic cholestane 
glycosides suggested that further phytochemical analysis of O. saundersiae bulbs could 
be beneficial.19 For the original isolation in 1992, 16.2 kg of bulbs were first extracted in 
methanol under reflux, and the methanolic fraction was then extracted with 1-butanol. 
The combined organic extractions were fractionated over silica gel column 
chromatography using CHCl3-MeOH gradient mixture as eluent. The partially-
fractionated components were further purified using a combination of chromatographic 
techniques, namely octadecyl-silica (ODS) column chromatography and preparative 
HPLC, to yield 25 mg of 1, 439 mg of 2 (OSW-1), and 23.5 mg of 3 (Figure 5).19 The 
detailed step-by-step procedure is summarized in Figure 22. 
 
Figure 22. Original isolation procedure summary 
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 The bulbs used in this work were cultivated in the OU Greenhouse by Mr. Lynn 
Nichols, harvested in June 2019 and stored at 0°C prior to extraction. To facilitate 
extraction, remove water, and increase yield by breaking cell integrity, the O. saundersiae 
bulbs were lyophilized overnight and physically ground using mortar and pestle. Two 
major extraction methods were investigated: one using a reflux condenser as performed 
in the literature19, and the other one involving a Soxhlet apparatus, method never reported 
for this plant (Figure 23).  
Similar amounts of O. saundersiae plant material were subjected to both extraction 
methods. In order to compare and validate results, the procedure was carried out 8 times. 
Figure 23. Comparison of extraction methods summary 
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A higher mass of extracted compounds was constantly observed by using a Soxhlet 
apparatus compared to a simple reflux condenser. This is presumably due to the fact that 
the compounds are extracted multiple times in a Soxhlet extraction. The advantage of this 
system is that instead of many portions of warm solvent being passed through the sample, 
just one batch of solvent is continuously recycled. Based on the larger amount of material 
extracted, the preliminary results supported use of the Soxhlet extraction method. 
 With the selected extraction method, a larger scale procedure was performed with 
more plant material. Ten O. saundersiae bulbs (308.6 g) were lyophilized overnight, 
resulting in a final mass of 153.3 g of bulk material. Dried bulbs were chopped into small 
pieces and extraction was carried out in 750 mL of hot MeOH using Soxhlet apparatus 
for 48 hours. After evaporation in vacuo, 63.9 g of crude methanolic liquid extract was 
obtained. The crude mixture was then diluted with 100 mL of DI H2O and partitioned 
three times with n-BuOH. The resulting combined organic phase was condensed to a 
crude butanol extract (1.51 g) while the aqueous phase was lyophilized to afford white 








Figure 24. Optimized extraction method summary 
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In order to indicate the presence of saponins and qualitatively verify the composition of 
both phases, a frothing test was performed.1 For that, 1 mL of the butanol extract was 
diluted with 20 mL of DI H2O and shaken in a graduated cylinder for 15 minutes. 
Development of stable foam suggests the presence of saponins.1 As expected, no foam 
formed in the aqueous phase, meaning that it did not contain any saponins. The butanol 
extract showed clear frothing. Natural products from the crude butanol extract were 
further separated through a developed, multi-stage purification processes. 
II.3.2 Purification and Analytical Method Development 
 Due to the unavailability of equipment described in the literature,19 a novel 
purification procedure was developed. The butanol extract was first analyzed by TLC 
prior to establishing an appropriate chromatographic separation method. Multiple elution 
conditions were tested (Figure 25). 
 Separation was optimal between 10-15% MeOH/CHCl3. In order to increase 
reproducibility of the method and obtain a consistent separation pattern, the 300 mg of 
the crude butanol extract was fractionated on automated silica gel column using Biotage 
Isolera, with linear gradient elution from 0-30% MeOH/CHCl3 and washed with EtOAc. 
Figure 25. TLCs of the butanol extract compared to OSW-1 tested with different 
elution conditions 
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Fractions with similar TLC profiles were combined and divided into 8 subfractions 
(Figure 26). 
 Each subfraction was then further purified and analyzed by reverse phase LC-MS 
Different separation conditions were investigated (Table 3). Variable parameters include 
column (C8, C18), mobile phase composition (MeCN, MeOH) and elution (isocratic, 
linear/step gradient). 
Column Solvent A 





C8 MeOH 80/20 Isocratic 0.60 
C8 MeOH 80/20 to 95/5 Linear gradient 0.61 
C8 MeCN 80/20 Isocratic 0.63 
C8 MeCN 80/20 to 100/0 Linear gradient 0.64 
C8 MeOH 75/25 Isocratic 0.68 
C8 MeOH 75/25 to 95/5 Linear gradient 0.67 
C8 MeCN 75/25 Isocratic 0.82 
C8 MeCN 75/25 to 100/0 Linear gradient 0.82 
C8 MeOH 70/30 Isocratic 0.71 
C8 MeOH 70/30 to 95/5 Linear gradient 0.72 
C8 MeCN 70/30 Isocratic 0.84 
C8 MeCN 70/30 to 100/0 Linear gradient 0.85 
C8 MeOH 65/35 Isocratic 0.65 
C8 MeOH 65/53 to 95/5 Linear gradient 0.62 
C8 MeCN 65/35 Isocratic 0.79 
C8 MeCN 65/53 to 100/0 Linear gradient 0.77 
C8 MeOH 75/25 to 85/15 to 95/5 Step gradient 1.02 
C8 MeCN 75/25 to 85/15 to 100/0 Step gradient 1.24 
Figure 26. First purification and fractionation of the crude butanol extract 
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C18 MeOH 80/20 Isocratic 0.72 
C18 MeOH 80/20 to 95/5 Linear gradient 0.72 
C18 MeCN 80/20 Isocratic 0.88 
C18 MeCN 80/20 to 100/0 Linear gradient 0.89 
C18 MeOH 75/25 Isocratic 0.75 
C18 MeOH 75/25 to 95/5 Linear gradient 0.73 
C18 MeCN 75/25 Isocratic 0.94 
C18 MeCN 75/25 to 100/0 Linear gradient 0.94 
C18 MeOH 70/30 Isocratic 0.78 
C18 MeOH 70/30 to 95/5 Linear gradient 0.80 
C18 MeCN 70/30 Isocratic 1.02 
C18 MeCN 70/30 to 100/0 Linear gradient 1.03 
C18 MeOH 75/25 to 85/15 to 95/5 Step gradient 0.98 
C18 MeCN 75/25 to 85/15 to 100/0 Step gradient 1.32 
C18 MeOH 70/30 to 85/15 to 95/5 Step gradient 1.08 
C18 MeCN 70/30 to 85/15 to 100/0 Step gradient 1.43 
Table 3. Screening of optimum HPLC separation conditions 
In order to quantitatively assess the best separation conditions, resolution factors were 
calculated for each chromatogram. A resolution factor of 1.5 or more is indicative of 
optimal peak separation.132  Compared to MeOH/H2O, MeCN/H2O gave overall superior 
HPLC separation quality (Table 3). Due to the heterogeneity of samples, a step gradient 
was preferred over a linear gradient and isocratic elution. Peak separation was ideal with 
a step gradient from 70/30 to 85/15 to 100/0 MeCN/H2O (with 0.1% formic acid), as 
resolution factor is close to 1.5.  
 The coupling of HPLC with MS is a powerful tool to identify both naturally-
occurring cholestane glycosides and their synthetic analogs. Three cholestane glycosides, 
including OSW-1 and two new analogs with modified steroidal side chains, thienyl-
OSW-1 (116, Appendix J) and silylated thienyl-OSW-1 (117, Appendix J), were 
analyzed by using optimized, reversed phase HPLC with electrospray ionization and 
atmospheric pressure chemical ionization quadrupole MS133,134 To the best of our 
knowledge, this is the only study that reported optimized MS techniques to complement 
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traditional characterization methods (NMR, IR) of OSW-1-derived compounds. Yet, this 
technique gives useful information, especially for the isolation, identification and 
structural elucidation of naturally-occurring analogs.135 
 In this work, monoisotopic masses were determined by MS via positive and 
negative electrospray ionization (ESI+ and ESI-). The following adducts of compounds 
were detected: [M+H]+, [M+Na]+, [M+K]+, [M+NH4]
+, [M+HCOO]-, [M+CH3COO]
-. 
Positive ESI mode  showed superior sensitivity and consistency in the MS detecting of 
OSW-1-related compounds than the negative ESI mode. As stated above, 0.1% formic 
acid (pKA= 3.75) was added to the water phase, thus promoting protonation of the 
hydroxyl groups (pKA≈16). Interestingly, sodium adducts peaks ([M+Na]
+) were 
predominantly detected in comparison with protonated adduct peaks ([M+H]+), despite 
the 0.1% of formic acid present. This is presumably due to the fact that sodium is one of 
the most abundant contaminants in all commercially available HPLC grade solvents.136 
Moreover, sodium can come from a number of sources, mainly during sample preparation 
and analysis: residual salts can be present on the column, in the HPLC system (injector, 
tubing, etc…) or sodium can leach from the glassware used to prepare the solvents.136 
 Based on all isolation studies, targeted cholestane glycosides have a molecular 
mass approximately ranging from 680-1100 g/mol.17,19,20,22–25,27,29,33,99–101 Therefore, all 
compounds with molecular ion peaks outside of this bracket were not considered relevant. 
Once the molecular ion peak was determined, a unique fragmentation pattern allowed us 
to further assess a compound’s structure (discussed in Section II.3.3 below). Relevant 
natural products were identified in subfractions F26-37 (D) and F38-45 (E). The ultimate 
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step of the entire procedure was to fractionate these subfractions by HPLC, resulting in 
isolated amounts of the various natural product compounds (Figure 27). 
 Purity was assessed by re-submitting isolated compound to HPLC analysis prior to 
preliminary characterization. Based on peak areas, compound was considered pure when 
purity ≥ 95%. 
II.3.3 Preliminary Characterization 
 Approximately 100 OSW-1 analogs were purified via reverse-phase HPLC 
(Appendix L-O), 6 of which were characterized (Figure 28). After purification and 
identification of molecular masses, preliminary characterization of each isolated natural 
product was achieved by 1H-NMR, MS, and by comparison with spectral data reported 
in literature. 17,19,20,22–25,27,29,33,99–101 
 
Figure 27. Ultimate step of the isolation procedure: fractionation of F26-37 (top) 






Figure 28. Overview of known and new characterized compounds 
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Characterization of 2 (OSW-1) 
 Compound 2 (Figure 28) was isolated as an amorphous solid by HPLC and had 
an m/z value of [M+Na]+ 895.25 and [M+H]+ 873.25 in ESI+  and 917.15 [M+HCOO]- in 
ESI- corresponding to a molecular weight of 873.03 g/mol and molecular formula 
C47H68O15. In accordance with literature, compound 2 was identified as OSW-1.
19,133 The 
1H-NMR data matched with the structure originally isolated.19 Moreover, the MS 
fragmentation pattern of OSW-1 was extensively studied in order to identify how the 
natural product is fragmented in the mass spectrometer, and to further help determine 
what part of the OSW-1-related compounds had changed in regard to OSW-1 (Figure 
29). This is not a common method, and to the best of our knowledge, the hypothesized 












OSW-1 Sodium Adduct 
C47H68O15Na 
Exact Mass: 895.45 
Figure 29. OSW-1 mass spectrum and fragmentation pattern 
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With the procedure being reiterated 8 times, OSW-1 was isolated multiple times. Due to 
the reproducibility of the analytical method, retention times recorded by HPLC were 
similar, and a total amount of 12 mg of OSW-1 was isolated.  
Characterization of 3 
 Compound 3 (Figure 28) was isolated as an amorphous solid by HPLC had an 
m/z value of 925.30 [M+Na]+ in ESI+ and 947.10 [M+HCOO]- in ESI-, corresponding to 
a molecular weight of 903.07 g/mol and molecular formula C48H70O16. This molecular 
formula matched the 3,4-dimethoxybenzoate analog of OSW-1.19 In a similar manner as 
described above, the MS fragmentation pattern of 3 was determined for the first time 
(Figure 30). 
Sodium Adduct of 3 
C48H70O16Na 
Exact Mass: 925.45 
Figure 30. Mass spectrum and fragmentation pattern of 3 
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Spectral data of 3 was almost identical with those of OSW-1. Comparison of the 1H 
spectra  of 2 (OSW-1) and 3 in deuterated acetonitrile (Figure 31) showed minor signal 
changes at δ 7.73 (dd, J = 8.5, 2.0 Hz, 2H), δ 7.61 (d, J = 2.0 Hz, 2H), and δ 7.06 (d, J = 
8.5 Hz, 1H) in the aromatic region, due to the disubstituted benzoyl moiety.  
With the procedure being reiterated 8 times, 3 was isolated multiple times. Due to the 
reproducibility of the analytical method, retention times recorded by HPLC were similar, 
and a total amount of 4 mg of 3 was isolated. Additionally, bulbs used in the original 
isolation procedure were not necessarily the same as the ones used in this work. 
Therefore, in order to assess whether the amount of 3 in regard to 2 (OSW-1) was similar 
to the literature, the ratio of 3 with respect to 2 was calculated and compared to literature. 
Originally, 23.5 mg of 3 and 439 mg of 2 were isolated, which is equivalent to a ratio of 
5.4%. In this work, the peak areas were used to determine that ratio (peak area of 3: 
Figure 31. 1H-NMR spectra comparison of OSW-1 (bottom) and IF-112 (top) 
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134,137; peak area of 2: 2,105,820), resulting in a value of 6.4%. These results are 
indicative of a consistent amount of 3 in regard to 2, regardless of the type of bulbs. 
Characterization of 4 
 Compound 4 (Figure 29) was isolated as an amorphous solid by HPLC and had 
an m/z value of [M+Na]+ 891.20 in ESI+, corresponding to a molecular weight of 869.06 
g/mol and molecular formula C48H68O14. This molecular formula matched the (E)-
Cinnamoyl analog of OSW-1.33 In a similar manner as described above, the MS 
fragmentation pattern of 4 was determined for the first time (Figure 32). 
Analysis of the 1H spectrum of 4 and comparison with 2 (OSW-1) (Figure 33) implied 
that 4 differed from OSW-1 only in terms of the aromatic constituent. The absence of the 
-CH3 peak at δ 3.86 indicated that 4 is not comprised of a 4-methoxybenzoyl group. 
Sodium Adduct of 4 
C48H68O14Na 
Exact Mass: 868.45 
Figure 32. Mass spectrum and fragmentation pattern of 4 
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Moreover, a significant change of signal was observed in the aromatic region at δ 7.65 
(m, 2H) and 7.46 – 7.40 (m, 4H), indicative of a non-substituted benzene ring, and at δ 
7.73 (d, J = 16.1 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), indicative of a the presence of alkene 
in trans configuration, supported by the coupling constants. 
With the procedure being reiterated 8 times, 4 was isolated multiple times. Due to the 
reproducibility of the analytical method, retention times recorded by HPLC were similar, 
and a total amount of 5 mg of 4 was isolated. 
Characterization of 9 
 Compound 9 (Figure 29) was isolated as an amorphous solid by HPLC and had 
an m/z value of [M+Na]+ 881.45 in ESI+, corresponding to a molecular weight of 859.02 
g/mol and molecular formula C46H66O15. In a similar manner as described above, the MS 
fragmentation pattern of 9 was determined for the first time (Figure 34). 








Analysis of the 1H spectrum of 9 and comparison with OSW-1 (Figure 35) implied that 
9 differed from OSW-1 only in terms of the aromatic acid constituent. Instead of the 
signals for the 4-methoxybenzoyl group, those assignable to a 4-hydroxybenzoyl residue 
were observed with the absence of the -CH3 peak at δ 3.86 and a slight downfield-shift of 
the aromatic protons  at δ 8.00 – 7.94 (d, 2H) and δ 6.96 – 6.91 (d, 2H).  
Figure 35. 1H-NMR spectra comparison of OSW-1 (top) and IF-148 (bottom) 
Sodium Adduct of 9 
C46H66O15Na 
Exact Mass: 881.45 
Figure 34. Sodium adduct and fragmentation pattern of 9 
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With the procedure being reiterated 8 times, 9 was isolated multiple times. Due to the 
reproducibility of the analytical method, retention times recorded by HPLC were similar, 
and a total amount of 6 mg of 9 was isolated.  
Characterization of 20  
 Compound 20 (Figure 29) was isolated as an amorphous solid by HPLC and had 
an m/z value of [M+Na]+ 779.40 in ESI+ and [M+HCOO]- 791.10 in ESI-, corresponding 
to a molecular weight of 756.97 g/mol and molecular formula C43H64O11. In a similar 
manner as described above, the MS fragmentation pattern of 9 was determined for the 
first time (Figure 36). 
The 1H-NMR spectrum showed signals for five steroidal methyl groups at δ 1.14 (s, 3H), 
1.00 (s, 3H), 0.94 – 0.86 (m, 3H + 8H), 0.75 (dd, J = 15.9, 6.6 Hz, 6H), an olefinic proton 
at δ 5.38 (d, J = 5.6 Hz, 1H), and the α-L-rhamnopyranosyl anomeric proton at δ 5.34 – 
5.30 (d, J= 2 Hz, 1H). Moreover, the aglycone was slightly modified with the presence of 
a hydroxyl group at the C-11 position showed by a proton signal at δ 4.66 (br. s, 1H). 
Two acyl moieties were linked to the rhamnoside, namely a p-methoxybenzoyl group at 
the C-3 position and an acetyl group linked at the C-2 position, supported by the presence 
Sodium Adduct of 20 
C43H64O11Na 
Exact Mass: 779.40 
Figure 36. Sodium adduct and fragmentation pattern of 20 
46 
of proton signals at δ 7.93 – 7.88 (d, J = 8.8 Hz, 2H), 7.00 – 6.94 (d, J = 8.8 Hz, 2H), 3.84 
(s, 3H, -OMe) and 1.61 (s, 3H, Ac). Reduction of the C-22 ketone present in OSW-1 to a 
C-22 hydroxyl group was demonstrated by the up-field shift of the C-20 proton at δ 3.27 
(s, 1H), the presence of a hydroxyl proton at δ 4.60 (br. s, 1H) and by the cluster of signal 
at δ 4.17-4.10 (m, 1H) indicative of the C-22 proton. With the procedure being reiterated 
8 times, 20 was isolated multiple times. Due to the reproducibility of the analytical 
method, retention times recorded by HPLC were similar, and a total amount of 4 mg of 
20 was isolated. 
Structural Elucidation of IF-111  
 Compound IF-111 (Figure 29) was isolated as an amorphous solid by HPLC and  
had an m/z value of [M+Na]+ 893.20 in ESI+, corresponding to a molecular weight of 
871.03 g/mol and molecular formula C47H66O15. In a similar manner as described above, 
the MS fragmentation pattern of IF-111 was determined for the first time (Figure 37). 
Figure 37. Mass spectrum and fragmentation pattern of IF-111 (new compound) 
Sodium Adduct of IF-111 
C47H66O15Na 
Exact Mass: 893.20 
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Analysis of the 1H spectrum of IF-111 and comparison with OSW-1 (Figure 40) implied 
that IF-111 differed from OSW-1 by 2 protons. This correlates with the peak signal 










The position of the alkene was investigated by observing the side chain region in the low 
ppm values, as the steroid core proton signals were unchanged. Three positions for the 
alkene were hypothesized (IF-111A, IF-111B, IF-111C, Figure 39).  
Figure 38. Zoom of the 1H-NMR alkene region of IF-
111 (bottom) compared to OSW-1 (top) 
Figure 39. Three possible positions of the additional alkene on IF-111 
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The C26 and C27 protons in the cluster of signals at δ 0.81 – 0.75 (m, 9H) in OSW-1 
were modified to a unique singlet of 6 equivalent protons at δ 0.90 (s, 6H). Moreover, the 
C25 proton in the region between δ 1.28 – 1.16 (m, 4H) does not appear in IF-111. The 
alkene was thus hypothesized to be positioned at the −C24-C25 position. 
The isolated amount of compound IF-111 was insufficient (2 mg) for 13C and 2D NMR 
analyses to confirm the putative structure.   
II.4 Conclusions and Future Directions 
 I have developed a novel and efficient analytical method to isolate and 
characterize several OSW-1 analogs. This reproducible method will allow for the 
isolation of OSW-1-related compounds on demand from the O. saundersiae bulbs.  One 
new OSW-1-related natural product, previously unreported, has been putatively 
Figure 40. 1H-NMR spectra comparison of OSW-1 (top) and IF-111 (bottom) 
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identified. In particular, the newly isolated natural product differs from OSW-1 by the 
presence of an unsaturation at the C24-25 position of the aliphatic side chain. Future 
isolations using the established method will provide sufficient material to confirm the 
structures through 13C NMR and 2D NMR analysis. I have additionally identified several  
parameters that could be further modulated to improve the isolation of OSW-1-related 
natural products, including exploring extraction solvent with different polarities (e.g, 
EtOH, EtOAc, hexanes, petroleum ether, etc…), the purification solvent system (e.g, 
MeOH/DCM, CHCl3/AcOH/MeOH/H2O), and the analytical method conditions (e.g, 
isocratic, altered gradient, MS parameters). Further, it would be interesting to process not 
only bulbs, but also leaves, flowers and stems of the O. saundersiae plant, to establish a 
basis of comparison and potentially discover new OSW-1 analogs to supplement SAR 
studies. Moreover, the analytical method can still be optimized. This can especially be 
done through reducing the analytical time requirements of sample analysis, and by using 
a succession of columns to increase the purity of compounds. Otherwise, mixtures of 
compounds can be tested for their activity through bioassay-guided fractionation to 
identify bioactive extracts more efficiently and isolate pure active compounds with 
potential increased binding affinity to OSBP and ORP4L. Even though cytotoxic 
activities of analogs have been reported for a tremendous amount of natural and synthetic 
analogs, many of these compounds have not been tested on resistant cancer-cell lines (e.g. 
ovarian cancer), which is currently investigated in our lab. 
 Additionally, creating molecular networks of all these steroidal saponins through 
the Global Natural Products Social Networking platform (GNPS) is a source of new 
opportunities related to the fields of analytical chemistry and metabolomics. Molecular 
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networking organizes the tandem MS/MS data as a relational spectral network thereby 
mapping the chemistry that was detected in an MS/MS-based metabolomics 
experiment.138 This has never been reported before for these compounds and is a worthy 
objective. If implemented to this research, these networks could provide more insight into 
biological activities. Molecular networking is just beginning to be recognized but is 
already studied for the discovery of therapeutic leads, monitoring drug metabolism, 
clinical diagnostics, and emerging applications in precision medicine.138,139 
 Most importantly, since there are currently no existing co-crystal structures of 
OSBP and ORP4L bound to OSW-1 or a related analog, achieving this objective would 
significantly enhance our understanding of OSW-1’s mechanism of action within cells, 
and ultimately lead to the development of potent antiviral and anticancer precision 
therapeutics capable of providing new therapies in human disease. 
The library of OSW-1-related natural products produced from this research, in 
addition to compounds currently being characterized, will be tested for binding to OSBP 
and ORP4L in the near future. This will allow us to further supplement current SAR 
studies of OSW-1 in regard  to OSBP and ORP4L, progressively guiding us toward the 
understanding of the compound’s molecular interactions with the proteins. Ultimately, 
the results collected from biological testing will promote the development of selective 
anti-viral and anti-cancer therapeutics with improved pharmacokinetic and 





II.5 Materials and Methods 
II.5.1 General Experimental Procedure 
 Lyophilization of plant material was performed using 2.5 L FreeZone Labconco 
Lyophilizer. Flash column chromatography was performed as described by Still et al.137 
employing E. Merck silica gel 60 (230-400 mesh ASTM). TLC analyses and preparative 
TLC (pTLC) purification were performed on 250 µm Silica Gel 60 F254 plates purchased 
from EM Science and Fluka Analytical. All solvents were used as purchased without 
further purification. Automated purifications were performed on Biotage Isolera One 
purification system using manually packed columns of 5G, 10G, 25G, or 50G of oven 
dried silica. 1H and 13C NMR spectra were recorded on a 400 MHz or 500 MHz Varian 
VNMRS DirectDrive spectrometer equipped with an indirect observe probe. Chemical 
shifts for proton and carbon resonances are reported in ppm (δ) relative to the residual 
protons in chloroform (δ 7.26), in acetonitrile [δ 1.94 (5)] and in methanol [δ 3.31 (5), δ 
4.78] as references. High-resolution mass spectrometry (HRMS) analysis was performed 
using Agilent 6538 high-mass-resolution QTOF mass spectrometer. HPLC purification 
was performed on Shimadzu LCMS 2020 system [LC-20AP (pump), SPD-M20A (diode 
array detector), LCMS-2020 (mass spectrometer)]. Semi-preparative HPLC purification 
was performed using Phenomenex Luna C-18(2) column, 5 µm particle size (250 mm x 
4.6 mm), supported by Phenomenex Security Guard cartridge kit C18 (4.0 mm x 3.0 mm); 
Phenomenex Luna C-8(2) column, 5 µm particle size (250 mm x 4.6 mm), supported by 
Phenomenex Security Guard cartridge kit C8 (4.0 mm x 3.0 mm) and HPLC-grade 
solvents (≥ 99.5%). 
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II.5.2 Plant Material 
 The Ornithogalum Saundersiae bulbs were cultivated in the OU greenhouse 
(Department of Microbiology and Plant Biology) by Mr. Lynn Nichols. Light was natural 
unless temperatures were above 98°F. In that case, there was 35% shading. Plants were 
fertilized every other week with 20-10-20 350 ppm N. Soil mix was 8 parts bm7 (35% 
composted bark, 10% perlite, 55% peat moss), 1 part turface (calcinated clay) and 1 part 
topsoil. Plants were harvested on June 21st, 2019 and stored at 0°C. 
II.5.3 Extraction and Isolation 
Fresh Ornithogalum saundersiae bulbs were lyophilized overnight, physically ground 
using mortar and pestle, and extracted with 750 mL of hot MeOH using Soxhlet 
apparatus. The extract was concentrated under reduced pressure, and the crude 
methanolic residue was diluted with 100 mL of DI H2O and extracted 3 times with 30 mL 
of n-BuOH. The n-BuOH-soluble phase was fractionated on automated silica gel column 
using Biotage Isolera, with linear gradient elution from 0-30% MeOH/CHCl3 and washed 
with EtOAc. Fractions with similar TLC profiles were combined and divided into 8 
subfractions (A-H). Subfractions D and E were further separated by HPLC-MS with a 
stepped gradient from 70/30 to 85/15 to 100/0 MeCN/H2O (with 0.1% formic acid) to 
yield compounds D1 (1.6 mg), D2 (3 mg), D3 (2.5 mg), D4 (3 mg), D5 (1 mg), D6 (2 
mg), D7 (1.6 mg), D8 (1.3 mg), E1 (2 mg), E2 (1.6 mg), E3 (1.3 mg), E4 (2 mg), E5 (1 
mg), E6 (< 1 mg), E7 (1 mg), E8 (4 mg) and E9 (< 1 mg). LC-MS samples were prepared 
by adding a volume of a 50/50 MeOH/MeCN solution such that the concentration was ~ 
10 mg/mL. Further analysis of these compounds and other fractions is now under way. 
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II.5.4 LC-MS Analysis Parameters 
LC-MS instrument parameters can be found as follows in Table 4. 
MS 
Acquisition Time (min) 33 min 
Acquisition Mode Scan 
m/z Range 200 – 1100 
Voltage (kV) 30 
INTERFACE 
DL Temperature (°C) 250 
Heat Block Temperature (°C) 400 
Nebulizing Gas Flow (mL/min) 1.5 
Drying Gas Flow (mL/min) 15 
PUMP 
Solvent A Acetonitrile (MeCN) 
Solvent B Water + 0.1% Formic Acid 
Total Flow (mL/min) 2.2 
Mode Binary Gradient 
Table 4. LC-MS Instrument Parameters 
 
LC gradient was set according to Table 5. 






Table 5. LC-MS Gradient 
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II.5.5 Compound Data Summary 
2 (OSW-1): 3β,17α-Dihydroxy-16β-[[O-(2-O-(4methoxybenzoyl)-β-D-xylopyranosyl)-






Molecular formula: C47H68O15; ESI-MS (positive mode): m/z [M+Na]
+ 895.25, [M+H]+ 
873.25; ESI-MS (negative mode): m/z [M+HCOO]- 917.15; M = 873.03 g/mol;  1H-NMR 
(500 MHz, Acetonitrile-d3) δ 8.05 – 7.97 (d, J = 8 Hz, 2H), 7.06 – 6.98 (d, J = 8 Hz, 2H), 
5.31 (d, J = 5.0 Hz, 1H), 4.87 – 4.81 (t, 1H), 4.73 (dd, J = 8.3, 6.2 Hz, 1H), 4.61 (d, J = 
7.7 Hz, 1H), 4.20 (s, 1H), 4.01 (d, J = 6.2 Hz, 1H), 3.92 (dd, J = 11.5, 5.1 Hz, 1H), 3.88 
(m, 1H), 3.86 (s, 3H), 3.76 (dd, J = 12.4, 4.2 Hz, 1H), 3.67 (dt, J = 8.9, 4.6 Hz, 2H), 3.63 
– 3.56 (m, 1H), 3.54 (t, J = 8.8 Hz, 1H), 3.42 (dd, J = 12.4, 2.3 Hz, 1H), 3.31 (s, 1H), 3.26 
(d, J = 9.7 Hz, 1H), 2.86 (q, J = 7.4 Hz, 1H), 2.69 (s, 1H), 2.46 (m, 1H), 1.82 (m, 2H), 
1.74 – 1.68 (m, 2H), 1.67 (s, 3H), 1.61 – 1.56 (m, 1H), 1.53 (m, 2H), 1.50 (d, J = 9.7 Hz, 
2H), 1.43 (d, J = 12.0 Hz, 1H), 1.41 – 1.29 (m, 2H), 1.28 – 1.16 (m, 4H), 1.07 (d, J = 7.4 
Hz, 3H), 1.03 (dd, J = 13.6, 3.8 Hz, 1H), 1.00 (s, 3H), 0.88 (m, 1H), 0.81 – 0.75 (m, 9H). 












Molecular formula: C48H70O16; ESI-MS (positive mode): m/z [M+Na]
+ 925.30; ESI-MS 
(negative mode): m/z [M+HCOO]- 947.10 ; M = 903.07 g/mol; 1H-NMR (500 MHz, 
Acetonitrile-d3) δ 7.73 (dd, J = 8.5, 2.0 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.06 (d, J = 8.5 
Hz, 1H), 5.34 (d, J = 5.1 Hz, 1H), 4.88 (t, J = 8.2 Hz, 1H), 4.79 – 4.73 (dd, 1H), 4.66 (d, 
J = 7.7 Hz, 1H), 4.22 (s, 1H), 4.04 (d, J = 6.0 Hz, 1H), 3.96 (dd, J = 11.5, 4.9 Hz, 1H), 
3.90 (2s, 6H), 3.79 (dd, J = 12.3, 4.5 Hz, 1H), 3.74 – 3.69 (m, 2H), 3.68 – 3.62 (m, 1H), 
3.59 (d, J = 8.9 Hz, 2H), 3.45 (dd, J = 11.2 Hz, 2.0 Hz, 1H), 3.30 (t, J = 11.2 Hz, 2H), 
2.89 (q, J = 7.4 Hz, 1H), 2.72 (s, 1H), 2.47 (m, 1H), 1.74 (m, 7H), 1.62 (m, 3H), 1.50 (m, 
5H), 1.43 (m, 1H), 1.38 (m, 2H), 1.26 (4H, m), 1.10 (d, J=7.4, 3H), 1.05 (m, 1H), 1.03 (s, 




















Molecular formula: C48H68O14; ESI-MS (positive mode): m/z [M+Na]
+ 891.50; M = 
869.06 g/mol; 1H-NMR (500 MHz, Acetonitrile-d3) δ 7.73 (d, J = 16.1 Hz, 1H), 7.65 (m, 
2H), 7.46 – 7.40 (m, 3H), 6.52 (d, J = 16.0 Hz, 1H), 5.29 (d, J = 5 Hz, 1H), 4.83 – 4.78 
(m, 1H), 4.75 (t, J = 8.5 Hz, 1H), 4.53 (d, J = 7.7 Hz, 1H), 4.21 (s, 1H), 4.04 (d, J = 6.6 
Hz, 1H), 3.89 (dd, J = 11.6, 5.3 Hz, 1H), 3.77 (dd, J = 12.6, 3.7 Hz, 1H), 3.73 – 3.64 (m, 
2H), 3.56 (m, 1H), 3.45 (dd, J = 17.1, 10.6 Hz, 1H), 3.24 (d, J = 10.8 Hz, 2H), 2.94 (q, J 
= 7.4 Hz, 1H), 2.69 (m, 1H), 2.34 (m, 1H), 1.99 (s, 3H), 1.72 (m, 2H), 1.52 (m, 5H), 1.36 
(m, 1H), 1.33 (m, 2H), 1.22 (m, 2H), 1.20 – 1.19 (m, 1H), 1.14 (m, 2H), 1.09 (d, J = 7.4 
Hz, 4H), 1.05 (s, 1H), 0.99 (s, 3H), 0.88 (m, 1H), 0.78 – 0.76 (m, 9H). See Appendix R 
for NMR spectrum.  
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Molecular formula: C46H66O15; ESI-MS (positive mode): m/z [M+Na]
+ 881.25; M = 
859.02 g/mol; 1H-NMR (500 MHz, Acetonitrile-d3) δ 8.00 – 7.94 (d, J = 8 Hz, 2H), 6.96 
– 6.91 (d, J= 8 Hz, 2H), 5.34 (d, J = 5.0 Hz, 1H), 4.87 (t, J = 8.3 Hz, 1H), 4.76 (dd, J = 
8.3, 6.2 Hz, 1H), 4.64 (d, J = 7.7 Hz, 1H), 4.24 (s, 1H), 4.04 (d, J = 6.2 Hz, 1H), 3.95 (dd, 
J = 11.6, 5.1 Hz, 1H), 3.91 (s, 1H), 3.80 (dd, J = 12.4, 4.2 Hz, 1H), 3.70 (dt, J = 7.8, 3.9 
Hz, 2H), 3.66 – 3.60 (m, 1H), 3.56 (t, J = 8.9 Hz, 1H), 3.45 (d, J = 12.3 Hz, 1H), 3.34 (d, 
J = 13.3 Hz, 1H), 3.28 (s, 1H), 2.89 (q, J = 7.4 Hz, 1H), 2.71 (d, J = 4.7 Hz, 1H), 2.51 (m, 
1H), 2.29 (m, 1H), 1.74 (m, 2H), 1.70 (s, 3H), 1.62 (m, 1H), 1.58 (m, 2H), 1.54 (d, J = 
10.0 Hz, 2H), 1.47 (m, 1H), 1.37 (dt, J = 13.2, 6.7 Hz, 2H), 1.31 – 1.23 (m, 4H), 1.11 (d, 
J = 7.4 Hz, 3H), 1.09 – 1.05 (m, 1H), 1.03 (s, 3H), 0.92 (m, 1H), 0.84 (d, J = 6.5 Hz, 6H), 


















Molecular formula C43H64O11; ESI-MS (positive mode): m/z [M+Na]
+ 779.40; ESI-MS 
(negative mode): m/z [M+HCOO]- 791.10; M = 756.97 g/mol;  1H-NMR (500 MHz, 
Acetonitrile-d3) δ 7.93 – 7.88 (d, J = 8.8 Hz, 2H), 7.00 – 6.94 (d, J = 8.8 Hz, 2H), 5.38 (d, 
J = 5.6 Hz, 1H), 5.34 – 5.30 (d, J= 2 Hz, 1H), 5.14 (dd, J = 9.7, 3.4 Hz, 1H), 5.11 (t, J = 
2.5 Hz, 1H), 4.85 (dd, J = 3.5, 1.6 Hz, 1H), 4.66 (br. s, 1H), 4.60 (br.s, 1H), 4.17-4.10 (m, 
1H), 3.95 (m, 1H), 3.84 (s, 3H), 3.80 – 3.75 (m, 1H), 3.72 – 3.54 (m, 4H), 3.46 (m, 2H), 
3.43 (s, 2H), 3.27 (s, 1H), 2.70 (m, 1H), 2.58 – 2.55 (td, J = 3.5 Hz, J = 13.9 Hz, 1H), 
1.69 (s, 3H), 1.61 (s, 3H), 1.47 (m, 7H), 1.14 (s, 3H), 1.00 (s, 3H), 0.94 – 0.86 (m, 11H), 



























Molecular formula: C47H66O15; ESI-MS (positive mode): m/z [M+Na]
+ 893.20; ESI-MS 
(negative mode): m/z [M+HCOO]- 915.10; M = 871.03 g/mol;  1H-NMR (500 MHz, 
Acetonitrile-d3) δ 8.03 – 8.00 (d, J = 8 Hz, 2H), 7.35 – 7.01 (d, J = 8 Hz, 2H), 5.36 (d, J 
= 5.2 Hz, 1H), 5.32 (d, J = 5.0 Hz, 1H), 4.87 – 4.82 (t, 1H), 4.75 (dd, J = 8.3, 6.2 Hz, 1H), 
4.61 (d, J = 7.7 Hz, 1H), 4.19 (s, 1H), 4.06 (m, 2H), 3.86 (s, 3H), 3.77 (m, 1H), 3.70 (m, 
1H), 3.61 (t, J = 4.6 Hz, 2H), 3.56 (m, 1H), 3.47 (t, J = 8.8 Hz, 1H), 3.42 (dd, J = 12.4, 
2.3 Hz, 1H), 3.27 (m, 1H), 3.11 (q, J = 9.7 Hz, 1H), 2.91 (d, J = 7.4 Hz, 1H), 2.69 (m, 
1H), 1.72 (m, 2H), 1.74 – 1.68 (m, 2H), 1.66 (s, 3H), 1.53 (m, 2H), 1.51 (m, 5H), 1.22 
(m, 4H), 1.07 (d, J = 7.4 Hz, 3H), 1.03 (dd, J = 13.6, 3.8 Hz, 1H), 1.02 (s, 3H), 0.88 (m, 
10H), 0.76 (s, 3H). See Appendix U for NMR spectrum.  
60 
References 
1. Auwal, M. S.; Saka, S.; Mairiga, I. A.; Sanda, K. A.; Shuaibu, A.; Ibrahim, A. 
Preliminary Phytochemical and Elemental Analysis of Aqueous and Fractionated 
Pod Extracts of Acacia Nilotica (Thorn Mimosa). Vet. Res. forum  an Int. Q. J. 
2014, 5 (2), 95–100. 
2. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The Traditional Medicine and Modern Medicine 
from Natural Products. Molecules 2016, 21 (5), 559–576. 
3. Mushtaq, S.; Abbasi, B. H.; Uzair, B.; Abbasi, R. Natural Products as Reservoirs 
of Novel Therapeutic Agents. EXCLI J. 2018, 17, 420–451. 
4. Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs over the 
Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod 2020, 83, 770–803. 
5. Klayman, D. L. et al. Isolation of Artemisinin (Qinghaosu) From Artemisia Annua 
Growing in the United States. J. Nat. Prod. 1984, 47 (4), 715–717. 
6. Wall, M. E. The Discovery of Camptothecin and Taxol. Am. Chem. Soc. 2003. 
7. Heinrich, M.; Teoh, H. L. Galanthamine from Snowdrop - The Development of a 
Modern Drug against Alzheimer’s Disease from Local Caucasian Knowledge. J. 
Ethnopharmacol. 2004, 92 (2–3), 147–162. 
8. Carlson, E. E. Natural Products as Chemical Probes. ACS Chem. Biol. 2010, 5 (7), 
639–653. 
9. Shen, B. A New Golden Age of Natural Products Drug Discovery. Cell 2015, 163 
(6), 1297–1300. 
10. Challinor, V. L.; De Voss, J. J. Open-Chain Steroidal Glycosides, a Diverse Class 
of Plant Saponins. Nat. Prod. Rep. 2013, 30 (3), 429–454. 
61 
11. Ashour, A. S.; El Aziz, M. M. A.; Gomha Melad, A. S. A Review on Saponins 
from Medicinal Plants: Chemistry, Isolation, and Determination. J. Nanomedicine 
Res. 2019, 7 (4), 282–288. 
12. El Barky, A.; Hussein, S. A.; Alm-Eldeen, A.-E.; Hafez, A.; Mohamed, T. 
Diabetes Management Saponins and Their Potential Role in Diabetes Mellitus; 
2017; Vol. 7. 
13. Sobolewska Agnieszka Galanty Karolina Grabowska Justyna Makowska-Wa, D.; 
Wróbel-Biedrawa Irma Podolak, D. Saponins as Cytotoxic Agents. Phytochem. 
Rev. 2020, 19, 139–189. 
14. Sparg, S. G.; Light, M. E.; Van Staden, J. Biological Activities and Distribution of 
Plant Saponins. J. Ethnopharmacol. 2004, 94 (2–3), 219–243. 
15. Akinmoladun, A. C.; Olaleye, M. T.; Farombi, E. O. Cardiotoxicity and 
Cardioprotective Effects of African Medicinal Plants; Elsevier Inc., 2014. 
16. Plančić, M.; Božin, B.; Kladar, N.; Rat, M.; Srđenović, B. Phytochemical Profile 
and Biological Activities of the Genus Ornithogalum L. (Hyacinthaceae). Biol. 
Serbica 2014, 36 (1), 3–17. 
17. Tang, Y.; Li, N.; Duan, J. A.; Tao, W. Structure, Bioactivity, and Chemical 
Synthesis of OSW-1 and Other Steroidal Glycosides in the Genus Ornithogalum. 
Chem. Rev. 2013, 113 (7), 5480–5514. 
18. Podolak, I.; Galanty, A.; Sobolewska, D. Saponins as Cytotoxic Agents: A 
Review. Phytochemistry Reviews. Phytochem Rev September 2010, pp 425–474. 
19. Kubo, S.; Mimaki, Y.; Terao, M.; Sashida, Y.; Nikaido, T.; Ohmoto, T. Acylated 
Cholestane Glycosides from the Bulbs of Ornithogalum Saundersiae. 
62 
Phytochemistry 1992, 31 (11), 3969–3973. 
20. Iguchi, T.; Kuroda, M.; Naito, R.; Watanabe, T.; Matsuo, Y.; Yokosuka, A.; 
Mimaki, Y. Cholestane Glycosides from Ornithogalum Saundersiae Bulbs and the 
Induction of Apoptosis in HL-60 Cells by OSW-1 through a Mitochondrial-
Independent Signaling Pathway. J. Nat. Med. 2019, 73 (1), 131–145. 
21. Chen, Q. W.; Gong, T.; Zhang, P. C.; Kong, J. Q. Seven New 1-Oxygenated 
Cholestane Glycosides from Ornithogalum Saundersiae. J. Asian Nat. Prod. Res. 
2020, 22 (3), 201–216. 
22. Kuroda, M.; Mimaki, Y.; Sashida, Y.; Nikaido, T.; Ohmoto, T. Structure of a 
Novel 22-Homo-23-Norcholestane Trisaccharide from Ornithogalum Saundersiae. 
Tetrahedron Lett. 1993, 34 (38), 6073–6076. 
23. Kuroda, M.; Mimaki, Y.; Sashida, Y.; Hirano, T.; Oka, K.; Dobashi, A. A Novel 
Cholestane Glycoside with Inhibitory Activity on Proliferation of Human PBL 
from O. Saundersiae Bulbs. Chem. Pharm. Bull. 1995, 43 (7), 1257–1259. 
24. Mimaki, Y.; Kuroda, M.; Sashida, Y.; Hirano, T.; Oka, K.; Dobashi, A.; Koshino, 
H.; Uzawa, J. Three Novel Rearranged Cholestane Glycosides from Ornithogalum 
Saundersiae Bulbs and Their Cytostatic Activities on Leukemia HL-60 and 
MOLT-4 Cells. Tetrahedron Lett. 1996, 37 (8), 1245–1248. 
25. Hirano, T.; Oka, K.; Mimaki, Y.; Kuroda, M.; Sashida, Y. Potent Growth 
Inhibitory Activity of a Novel Ornithogalum Cholestane Glycoside on Human 
Cells: Induction of Apoptosis in Promyelocytic Leukemia HL-60 Cells. Life Sci. 
1996, 58 (9), 789–798. 
26. Mimaki, Y. Structures and Biological Activities of Plant Glycosides. Nat. procuts 
63 
Commun. 2006, 1 (3), 247–253. 
27. Kuroda, M.; Mimaki, Y.; Sashida, Y. Saundersiosides C-H, Rearranged 
Cholestane Glycosides from the Bulbs of Ornithogalum Saundersiae and Their 
Cytostatic Activity on HL-60 Cells. Phytochemistry 1999, 52 (3), 435–443. 
28. Kuroda, M.; Mimaki, Y.; Yokosuka, A.; Sashida, Y.; Beutler, J. A. Cytotoxic 
Cholestane Glycosides from the Bulbs of Ornithogalum Saundersiae. J. Nat. Prod. 
2001, 64 (1), 88–91. 
29. Iguchi, T.; Kuroda, M.; Naito, R.; Watanabe, T.; Matsuo, Y.; Yokosuka, A.; 
Mimaki, Y. Structural Characterization of Cholestane Rhamnosides from 
Ornithogalum Saundersiae Bulbs and Their Cytotoxic Activity against Cultured 
Tumor Cells. Molecules 2017, 22 (8). 
30. Morzycki, J. W.; Wojtkielewicz, A. Synthesis of a Highly Potent Antitumor 
Saponin OSW-1 and Its Analogues. Phytochem. Rev. 2005, 4 (2–3), 259–277. 
31. Yan, K.; Gao, L. N.; Cui, Y. L.; Zhang, Y.; Zhou, X. The Cyclic AMP Signaling 
Pathway: Exploring Targets for Successful Drug Discovery (Review). Mol. Med. 
Rep. 2016, 13 (5), 3715–3723. 
32. Lerner, A.; Epstein, P. M. Cyclic Nucleotide Phosphodiesterases as Targets for 
Treatment of Haematological Malignancies. Biochem. J. 2006, 393 (1), 21–41. 
33. Mimaki, Y.; Kuroda, M.; Kameyama, A.; Sashida, Y.; Hirano, T.; Oka, K.; 
Mafkawa, R.; Wada, T.; Sug, K.; Beutler, J. A. Cholestane Glycosides with Potent 
Cytotoxic Activities on Various Tumor Cells from Ornithogalum Saundersiae 
Bulbs. Bioorganic Med. Chem. Lett. 1997, 7 (5), 633–636. 
34. Zhang, Y.; Fang, F.; Fan, K.; Zhang, Y.; Zhang, J.; Guo, H.; Yu, P.; Ma, J. 
64 
Effective Cytotoxic Activity of OSW-1 on Colon Cancer by Inducing Apoptosis 
in Vitro and in Vivo. Oncol. Rep. 2017, 37 (6), 3509–3519. 
35. Zhou, Y.; Garcia-Prieto, C.; Carney, D. A.; Xu, R. hua; Pelicano, H.; Kang, Y.; 
Yu, W.; Lou, C.; Kondo, S.; Liu, J.; Harris, D. M.; Estrov, Z.; Keating, M. J.; Jin, 
Z.; Huang, P. OSW-1: A Natural Compound with Potent Anticancer Activity and 
a Novel Mechanism of Action. J. Natl. Cancer Inst. 2005, 97 (23), 1781–1785. 
36. Zhu, J.; Xiong, L.; Yu, B.; Wu, J. Apoptosis Induced by a New Member of Saponin 
Family Is Mediated through Caspase-8-Dependent Cleavage of Bcl-2. Mol. 
Pharmacol. 2005, 68 (6), 1831–1838. 
37. Péresse, T.; Kovacs, D.; Subra, M.; Bigay, J.; Antonny, B.; Mesmin, B. et al. 
Molecular and Cellular Dissection of the Oxysterol-Binding Protein Cycle through 
a Fluorescent Inhibitor. J. Biol. Chem. 2020, 295 (13), 4277–4288. 
38. Zhong, W.; Xu, M.; Li, C.; Olkkonen, V. M.; Lei, P.; Yan, D. et al. ORP4L Extracts 
and Presents PIP 2 from Plasma Membrane for PLCβ3 Catalysis: Targeting It 
Eradicates Leukemia Stem Cells. Cell Rep. 2019, 26 (8), 2166-2177.e9. 
39. Olkkonen, V. M. OSBP-Related Proteins: Liganding by Glycerophospholipids 
Opens New Insight into Their Function. Molecules 2013, 18 (11), 13666–13679. 
40. Burgett, A. W. G.; Shair, M. D. et al. Natural Products Reveal Cancer Cell 
Dependence on Oxysterol-Binding Proteins. Nat. Chem. Biol. 2011, 7 (9), 639–
647. 
41. Garcia-Prieto, C.; Ahmed, K. B. R.; Chen, Z.; Zhou, Y.; Hammoudi, N.; Kang, Y.; 
Lou, C.; Mei, Y.; Jin, Z.; Huang, P. Effective Killing of Leukemia Cells by the 
Natural Product OSW-1 through Disruption of Cellular Calcium Homeostasis. J. 
65 
Biol. Chem. 2013, 288 (5), 3240–3250. 
42. Charman, M.; Colbourne, T. R.; Pietrangelo, A.; Kreplak, L.; Ridgway, N. D. 
Oxysterol-Binding Protein (OSBP)-Related Protein 4 (ORP4) Is Essential for Cell 
Proliferation and Survival. J. Biol. Chem. 2014, 289 (22), 15705–15717. 
43. Shah, A. Development of Novel Anticancer Agents Based on Natural Products. 
2015, 1–205. 
44. Li, J. W.; Xiao, Y. L.; Lai, C. F.; Lou, N.; Ma, H. L.; Zhu, B. Y.; Zhong, W. Bin; 
Yan, D. G. Oxysterol-Binding Protein-Related Protein 4L Promotes Cell 
Proliferation by Sustaining Intracellular Ca 2+ Homeostasis in Cervical Carcinoma 
Cell Lines. Oncotarget 2016, 7 (40), 65849–65861. 
45. Zhong, W.; Olkkonen, V. M.; Yan, D. et al. ORP4L Is Essential for T-Cell Acute 
Lymphoblastic Leukemia Cell Survival. Nat. Commun. 2016, 7, 1–14. 
46. Kimura, M.; Sasaki, K.; Fukutani, Y.; Yoshida, H.; Ohsawa, I.; Yohda, M.; 
Sakurai, K. Anticancer Saponin OSW-1 Is a Novel Class of Selective Golgi Stress 
Inducer. Bioorganic Med. Chem. Lett. 2019, 29 (14), 1732–1736. 
47. Liu, H.; Huang, S. Role of Oxysterol-Binding Protein-Related Proteins in 
Malignant Human Tumours. World J. Clin. Cases 2020, 8 (1), 1–10. 
48. Albulescu, L.; Strating, J. R. P. M.; Thibaut, H. J.; Van Der Linden, L.; Shair, M. 
D.; Neyts, J.; Van Kuppeveld, F. J. M. Broad-Range Inhibition of Enterovirus 
Replication by OSW-1, a Natural Compound Targeting OSBP. Antiviral Res. 
2015, 117, 110–114. 
49. Albulescu, L.; Weber-Boyvat, M.; Olkkonen, V. M.; van Kuppeveld, F. J. M.; 
Strating, J. R. P. M. et al. Uncovering Oxysterol-Binding Protein (OSBP) as a 
66 
Target of the Anti-Enteroviral Compound TTP-8307. Antiviral Res. 2017, 140, 37–
44. 
50. Jaworski, C. J.; Moreira, E.; Li, A.; Lee, R.; Rodriguez, I. R. A Family of 12 
Human Genes Containing Oxysterol-Binding Domains. Genomics 2001, 78 (3), 
185–196. 
51. Lehto, M.; Laitinen, S.; Chinetti, G.; Johansson, M.; Ehnholm, C.; Staels, B.; 
Ikonen, E.; Olkkonen, V. M. The OSBP-Related Protein Family in Humans. J. 
Lipid Res. 2001, 42 (8), 1203–1213. 
52. Anniss, A. M.; Apostolopoulos, J.; Dworkin, S.; Purton, L. E.; Sparrow, R. L. An 
Oxysterol-Binding Protein Family Identified in the Mouse. DNA Cell Biol. 2002, 
21 (8), 571–580. 
53. Raychaudhuri, S.; Prinz, W. A. The Diverse Functions of Oxysterol-Binding 
Proteins. Annu. Rev. Cell Dev Biol 2010, 26, 157–177. 
54. Olkkonen, V. M.; Zhou, Y.; Yan, D.; Vihervaara, T. Oxysterol-Binding Proteins-
Emerging Roles in Cell Regulation. Eur. J. Lipid Sci. Technol. 2012, 114 (6), 634–
643. 
55. Weber-Boyvat, M.; Zhong, W.; Yan, D.; Olkkonen, V. M. Oxysterol-Binding 
Proteins: Functions in Cell Regulation beyond Lipid Metabolism. Biochem. 
Pharmacol. 2013, 86 (1), 89–95. 
56. Kentala, H.; Weber-Boyvat, M.; Olkkonen, V. M. OSBP-Related Protein Family: 
Mediators of Lipid Transport and Signaling at Membrane Contact Sites; Elsevier 
Inc., 2016; Vol. 321. 
57. Levine, T. P.; Munro, S. The Pleckstrin Homology Domain of Oxysterol-Binding 
67 
Protein Recognises a Determinant Specific to Golgi Membranes. Curr. Biol. 1998, 
8 (13), 729–739. 
58. Furuita, K.; Jee, J. G.; Fukada, H.; Mishima, M.; Kojima, C. Electrostatic 
Interaction between Oxysterol-Binding Protein and VAMP-Associated Protein a 
Revealed by NMR and Mutagenesis Studies. J. Biol. Chem. 2010, 285 (17), 
12961–12970. 
59. Manik, M. K.; Yang, H.; Tong, J.; Im, Y. J. Structure of Yeast OSBP-Related 
Protein Osh1 Reveals Key Determinants for Lipid Transport and Protein Targeting 
at the Nucleus-Vacuole Junction. Structure 2017, 25 (4), 617-629.e3. 
60. Olkkonen, V. M. OSBP-Related Protein Family in Lipid Transport over Membrane 
Contact Sites. Lipid Insights 2015, 2015, 1–9. 
61. Wyles, J. P.; Perry, R. J.; Ridgway, N. D. Characterization of the Sterol-Binding 
Domain of Oxysterol-Binding Protein (OSBP)-Related Protein 4 Reveals a Novel 
Role in Vimentin Organization. Exp. Cell Res. 2007, 313 (7), 1426–1437. 
62. Kandutschs, A. A.; Thompson, E. B. Cytosolic Proteins That Bind Oxygenated 
Sterols. Biol. Chem. 1980, 255 (22), 10813–10826. 
63. Soffientini, U.; Graham, A. Intracellular Cholesterol Transport Proteins: Roles in 
Health and Disease. Clin. Sci. 2016, 130 (21), 1843–1859. 
64. Roberts, B. L.; Severance, Z. C.; Bensen, R. C.; Le-McClain, A. T.; Malinky, C. 
A.; Mettenbrink, E. M.; Nuñez, J. I.; Reddig, W. J.; Blewett, E. L.; Burgett, A. W. 
G. Differing Activities of Oxysterol-Binding Protein (OSBP) Targeting Anti-Viral 
Compounds. Antiviral Res. 2019, 170 (June), 104548. 
65. Wang, A. P.; Weng, J.; Anderson, R. G. W.; Science, S.; Series, N.; Mar, N. OSBP 
68 
Is a Cholesterol-Regulated Scaffolding Protein in Control of ERK1 / 2 Activation. 
Science (80-. ). 2005, 307 (5714), 1472–1476. 
66. Wang, P. Y.; Weng, J.; Lee, S.; Anderson, R. G. W. The N Terminus Controls 
Sterol Binding While the C Terminus Regulates the Scaffolding Function of 
OSBP. J. Biol. Chem. 2008, 283 (12), 8034–8045. 
67. Wang, C.; JeBailey, L.; Ridgway, N. D. Oxysterol-Binding-Protein (OSBP)-
Related Protein 4 Binds 25-Hydroxycholesterol and Interacts with Vimentin 
Intermediate Filaments. Biochem. J. 2002, 361 (3), 461–472. 
68. Tong, J.; Yang, H.; Yang, H.; Eom, S. H.; Im, Y. J. Structure of Osh3 Reveals a 
Conserved Mode of Phosphoinositide Binding in Oxysterol-Binding Proteins. 
Structure 2013, 21 (7), 1203–1213. 
69. Beh, C. T.; Cool, L.; Phillips, J.; Rine, J. Overlapping Functions of the Yeast 
Oxysterol-Binding Protein Homologues. Genetics 2001, 157 (3), 1117–1140. 
70. Im, Y. J.; Raychaudhuri, S.; Prinz, W. A.; Hurley, J. H. Structural Mechanism for 
Sterol Sensing and Transport by OSBP-Related Proteins. Nature 2005, 437 (7055), 
154–158. 
71. Suchanek, M.; Hynynen, R.; Wohlfahrt, G.; Lehto, M.; Johansson, M.; Saarinen, 
H.; Radzikowska, A.; Thiele, C.; Olkkonen, V. M. The Mammalian Oxysterol-
Binding Protein-Related Proteins (ORPs) Bind 25-Hydroxycholesterol in an 
Evolutionary Conserved Pocket. Biochem. J. 2007, 405 (3), 473–480. 
72. Singh, R. P.; Brooks, B. R.; Klauda, J. B. Binding and Release of Cholesterol in 
the Osh4 Protein of Yeast. Proteins Struct. Funct. Bioinforma. 2009, 75 (2), 468–
477. 
69 
73. Bukiya, A. N.; Dopico, A. M. Common Structural Features of Cholesterol Binding 
Sites in Crystallized Soluble Proteins. J. Lipid Res. 2017, 58 (6), 1044–1054. 
74. Moser, B. R. Review of Cytotoxic Cephalostatins and Ritterazines: Isolation and 
Synthesis. J. Nat. Prod. 2008, 71 (3), 487–491. 
75. Komiya, T.; Yoshida, M.; Fukuoka, M.; Nakagawa, K. et al. Ritterazine B, a New 
Cytotoxic Natural Compound, Induces Apoptosis in Cancer Cells. Cancer 
Chemother. Pharmacol. 2003, 51 (3), 202–208. 
76. Beutler, J. A.; Shoemaker, R. H.; Johnson, T.; Boyd, M. R. Cytotoxic Geranyl 
Stilbenes from Macaranga Schweinfurthii. J. Nat. Prod. 1998, 61 (12), 1509–1512. 
77. Tasdemir, D.; Mangalindan, G. C.; Ireland, C. M. et al. Bioactive Isomalabaricane 
Triterpenes from the Marine Sponge Rhabdastrella Globostellata. J. Nat. Prod. 
2002, 65 (2), 210–214. 
78. Du, X.; Turner, N.; Yang, H. The Role of Oxysterol-Binding Protein and Its 
Related Proteins in Cancer. Semin. Cell Dev. Biol. 2018, 81, 149–153. 
79. Olkkonen, V. M. ORP4L: Can Targeting an MCS Component Provide Tools for 
Eradication of Leukemia? Contact 2019, 2, 251525641984052. 
80. Lehto, M.; Olkkonen, V. M. The OSBP-Related Proteins: A Novel Protein Family 
Involved in Vesicle Transport, Cellular Lipid Metabolism, and Cell Signalling. 
Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 2003, 1631 (1), 1–11. 
81. Mesmin, B.; Bigay, J.; Moser Von Filseck, J.; Lacas-Gervais, S.; Drin, G.; 
Antonny, B. A Four-Step Cycle Driven by PI(4)P Hydrolysis Directs Sterol/PI(4)P 
Exchange by the ER-Golgi Tether OSBP. Cell 2013, 155 (4), 830. 
82. Pietrangelo, A.; Ridgway, N. D. Bridging the Molecular and Biological Functions 
70 
of the Oxysterol-Binding Protein Family. Cell. Mol. Life Sci. 2018, 75 (17), 3079–
3098. 
83. Strating, J. R. P. M.; van der Linden, L.; Albulescu, L.; Bigay, J.; Shair, M. D.; 
Olkkonen, V. M.; van Kuppeveld, F. J. M. et al. Itraconazole Inhibits Enterovirus 
Replication by Targeting the Oxysterol-Binding Protein. Cell Rep. 2015, 10 (4), 
600–615. 
84. Park, I. W.; Ndjomou, J.; Wen, Y.; Liu, Z.; Ridgway, N. D.; Kao, C. C.; He, J. J. 
Inhibition of HCV Replication by Oxysterol-Binding Protein-Related Protein 4 
(ORP4) through Interaction with HCV NS5B and Alteration of Lipid Droplet 
Formation. PLoS One 2013, 8 (9), 1–18. 
85. Meutiawati, F.; Bezemer, B.; Strating, J. R. P. M.; Overheul, G. J.; Žusinaite, E.; 
van Kuppeveld, F. J. M.; van Cleef, K. W. R.; van Rij, R. P. Posaconazole Inhibits 
Dengue Virus Replication by Targeting Oxysterol-Binding Protein. Antiviral Res. 
2018, 157, 68–79. 
86. Wang, H.; Perry, J. W.; Lauring, A. S.; Neddermann, P.; De Francesco, R.; Tai, A. 
W. Oxysterol-Binding Protein Is a Phosphatidylinositol 4-Kinase Effector 
Required for HCV Replication Membrane Integrity and Cholesterol Trafficking. 
Gastroenterology 2014, 146 (5), 1373-1385.e11. 
87. Lin, J.-Y.; Kung, Y.-A.; Shih, S.-R. Antivirals and Vaccines for Enterovirus A71. 
88. Amako, Y.; Sarkeshik, A.; Hotta, H.; Yates, J.; Siddiqui, A. Role of Oxysterol 
Binding Protein in Hepatitis C Virus Infection. J. Virol. 2009, 83 (18), 9237–9246. 
89. Pietrangelo, A.; Ridgway, N. D. Bridging the Molecular and Biological Functions 
of the Oxysterol-Binding Protein Family. Cell. Mol. Life Sci. 2018, 75 (17), 3079–
71 
3098. 
90. Bugert, J. J.; Hucke, · F; Zanetta, · P; Bassetto, · M; Brancale, · A. Antivirals in 
Medical Biodefense. Virus Genes 2020, 1–18. 
91. Litterman, N.; Lipinski, C.; Ekins, S.; Lipinski, C. A. Small Molecules with 
Antiviral Activity against the Ebola Virus. 2015. 
92. Bauer, L.; Albulescu, L.; van Kuppeveld, F. J. M.; Strating, J. R. P. M. et al. 
Structure-Activity Relationship Study of Itraconazole, a Broad-Range Inhibitor of 
Picornavirus Replication That Targets Oxysterol-Binding Protein (OSBP). 
Antiviral Res. 2018, 156, 55–63. 
93. Mesmin, B.; Bigay, J.; Polidori, J.; Jamecna, D.; Lacas‐Gervais, S.; Antonny, B.  
Sterol Transfer, PI 4P Consumption, and Control of Membrane Lipid Order by 
Endogenous OSBP . EMBO J. 2017, 36 (21), 3156–3174. 
94. Altan-Bonnet, N. Lipid Tales on Viral Replication and Transmission. Trends Cell 
Biol. 2017, 27 (3), 201–213. 
95. Burgett, A. W. G.; Kothapalli, N. R.; Wu, S.; Severance, Z. C.; Bensen, R. C.; Le, 
A. T.; Roberts, B. L.; Nuñez, J. I.; Ma, H.; Standke, S. J.; Yang, Z.; Reddig, W. J.; 
Blewett, E. L. Transient Compound Treatment Induces a Multigenerational 
Reduction of Oxysterol-Binding Protein (OSBP) Levels and Prophylactic 
Antiviral Activity. ACS Chem. Biol. 2019. 
96. Cragg, G. M.; Newman, D. J. Antineoplastic Agents from Natural Sources: 
Achievements and Future Directions. Expert Opin. Investig. Drugs 2000, 9 (12), 
2783–2797. 
97. Suggitt, M.; Bibby, M. C. 50 Years of Preclinical Anticancer Drug Screening: 
72 
Empirical to Target-Driven Approaches. Clin. Cancer Res. 2005, 11 (3), 971–981. 
98. Gottesman, M. M. Mechanisms of Cancer Drug Resistance. Annu. Rev. Med. 2002, 
53 (1), 615–627. 
99. Mimaki, Y.; Kuroda, M.; Kameyama, A.; Sashida, Y.; Hirano, T.; Oka, K.; Koike, 
K.; Nikaido, T. A New Cytotoxic Cholestane Bisdesmoside from Ornithogalum 
Saundersiae Bulbs. Biosci. Biotechnol. Biochem. 1996, 60 (6), 1049–1050. 
100. Mimaki, Y.; Kuroda, M.; Sashida, Y.; Kameyama, A.; Hirano, T.; Oka, K.; 
Dobashi, A. A New Rearranged Cholestane Glycoside. Bioorganic Med. Chem. 
Lett. 1996, 6 (22), 2635–2638. 
101. Kuroda, M.; Mimaki, Y.; Sashida, Y.; Hirano, T.; Oka, K.; Dobashi, A.; Li, H. Y.; 
Harada, N. Novel Cholestane Glycosides from the Bulbs of Ornithogalum 
Saundersiae and Their Cytostatic Activity on Leukemia HL-60 and MOLT-4 Cells. 
Tetrahedron 1997, 53 (34), 11549–11562. 
102. Iguchi, T.; Kuroda, M.; Naito, R.; Watanabe, T.; Matsuo, Y.; Yokosuka, A.; 
Mimaki, Y. Cholestane Glycosides from Ornithogalum Saundersiae Bulbs and the 
Induction of Apoptosis in HL-60 Cells by OSW-1 through a Mitochondrial-
Independent Signaling Pathway. J. Nat. Med. 2019, 73 (1), 131–145. 
103. Chen, Q. W.; Zhang, X.; Gong, T.; Gao, W.; Yuan, S.; Zhang, P. C.; Kong, J. Q. 
Structure and Bioactivity of Cholestane Glycosides from the Bulbs of 
Ornithogalum Saundersiae Baker. Phytochemistry 2019, 164 (March), 206–214. 
104. Deng, S.; Yu, B.; Lou, Y.; Hui, Y. First Total Synthesis of an Exceptionally Potent 
Antitumor Saponin, OSW-1. J. Org. Chem. 1999, 64, 202–208. 
105. Morzycki, J. W.; Wojtkielewicz, A. Synthesis of a Cholestane Glycoside OSW-1 
73 
with Potent Cytostatic Activity. Carbohydr. Res. 2002, 337 (14), 1269–1274. 
106. Xue, J.; Liu, P.; Pan, Y.; Guo, Z. A Total Synthesis of OSW-1. J. Org. Chem. 2008, 
73 (1), 157–161. 
107. Yu, W.; Jin, Z. A New Strategy for the Stereoselective Introduction of Steroid Side 
Chain via α-Alkoxy Vinyl Cuprates: Total Synthesis of a Highly Potent Antitumor 
Natural Product OSW-1 [2]. J. Am. Chem. Soc. 2001, 123 (14), 3369–3370. 
108. Wojtkielewicz, A.; Długosz, M.; Maj, J.; Morzycki, J. W.; Nowakowski, M.; 
Renkiewicz, J.; Strnad, M.; Swaczynová, J.; Wilczewska, A. Z.; Wójcik, J. New 
Analogues of the Potent Cytotoxic Saponin OSW-1. J. Med. Chem. 2007, 50 (15), 
3667–3673. 
109. Zheng, D.; Zhou, L.; Guan, Y.; Chen, X.; Zhou, W.; Chen, X.; Lei, P. Synthesis of 
Cholestane Glycosides Bearing OSW-1 Disaccharide or Its 1→4-Linked Analogue 
and Their Antitumor Activities. Bioorganic Med. Chem. Lett. 2010, 20 (18), 5439–
5442. 
110. Guan, Y.; Zheng, D.; Zhou, L.; Wang, H.; Yan, Z.; Wang, N.; Chang, H.; She, P.; 
Lei, P. Synthesis of 5(6)-Dihydro-OSW-1 Analogs Bearing Three Kinds of 
Disaccharides Linking at 15-Hydroxy and Their Antitumor Activities. Bioorganic 
Med. Chem. Lett. 2011, 21 (10), 2921–2924. 
111. Maj, J.; Morzycki, J. W.; Rárová, L.; Oklešt’Ková, J.; Strnad, M.; Wojtkielewicz, 
A. Synthesis and Biological Activity of 22-Deoxo-23-Oxa Analogues of Saponin 
OSW-1. J. Med. Chem. 2011, 54 (9), 3298–3305. 
112. Sakurai, K.; Takeshita, T.; Hiraizumi, M.; Yamada, R. Synthesis of OSW-1 
Derivatives by Site-Selective Acylation and Their Biological Evaluation. Org. 
74 
Lett. 2014, 16 (24), 6318–6321. 
113. Liu, C.; Wang, A. peng; Jin, L.; Guo, Y.; Li, Y.; Zhao, Z.; Lei, P. Synthesis, 
Conformational Analysis and SAR Research of OSW-1 Analogues. Tetrahedron 
2016, 72 (27–28), 4091–4102. 
114. Sakurai, K.; Hiraizumi, M.; Isogai, N.; Komatsu, R.; Shibata, T.; Ohta, Y. 
Synthesis of a Fluorescent Photoaffinity Probe of OSW-1 by Site-Selective 
Acylation of an Inactive Congener and Biological Evaluation. Chem. Commun. 
2017, 53 (3), 517–520. 
115. Komatsu, R.; Sakurai, K. Development of Chemical Probes for Functional 
Analysis of Anticancer Saponin OSW-1. Chem. Rec. 2019, 19 (12), 2362–2369. 
116. Xu, Q. H.; Peng, X. W.; Tian, W. S. A New Strategy for Synthesizing the Steroids 
with Side Chains from Steroidal Sapogenins: Synthesis of the Aglycone of OSW-
1 by Using the Intact Skeleton of Diosgenin. Tetrahedron Lett. 2003, 44 (52), 
9375–9377. 
117. Deng, L.-H.; Wu, H.; Yu, B.; Jiang, M.-R.; Wu, J.-R. Synthesis of 5,6-Dihydro-
OSW-1 and Its Antitumor Activities. Chinese J. Chem. 2004, 22 (9), 994–998. 
118. Deng, L.; Wu, H.; Yu, B.; Jiang, M.; Wu, J. Synthesis of OSW-1 Analogs with 
Modified Side Chains and Their Antitumor Activities. Bioorganic Med. Chem. 
Lett. 2004, 14 (11), 2781–2785. 
119. Morzycki, J. W.; Wojtkielewicz, A.; Wołczyński, S. Synthesis of Analogues of a 
Potent Antitumor Saponin OSW-1. Bioorganic Med. Chem. Lett. 2004, 14 (12), 
3323–3326. 
120. Matsuya, Y.; Masuda, S.; Ohsawa, N.; Adam, S.; Tschamber, T.; Eustache, J.; 
75 
Kamoshita, K.; Sukenaga, Y.; Nemoto, H. Synthesis and Antitumor Activity of the 
Estrane Analogue of OSW-1. European J. Org. Chem. 2005, No. 5, 803–808. 
121. Shi, B.; Tang, P.; Hu, X.; Liu, J. O.; Yu, B. OSW Saponins: Facile Synthesis 
toward a New Type of Structures with Potent Antitumor Activities. J. Org. Chem. 
2005, 70 (25), 10354–10367. 
122. Qin, H. J.; Tian, W. S.; Lin, C. W. A Highly Efficient Synthesis of 22-Deoxy-
OSW-1 by Utilizing the Intact Skeleton of Diosgenin. Tetrahedron Lett. 2006, 47 
(19), 3217–3219. 
123. Tang, P.; Mamdani, F.; Hu, X.; Liu, J. O.; Yu, B. Synthesis of OSW Saponin 
Analogs with Modified Sugar Residues and Their Antiproliferative Activities. 
Bioorganic Med. Chem. Lett. 2007, 17 (4), 1003–1007. 
124. Fukaya, K.; Urabe, D.; Hiraizumi, M.; Noguchi, K.; Matsumoto, T.; Sakurai, K. 
Computational and Experimental Analysis on the Conformational Preferences of 
Anticancer Saponin OSW-1. J. Org. Chem. 2020, 85 (2), 339–344. 
125. Guo, C.; Fuchs, P. L. The First Synthesis of the Aglycone of the Potent Anti-Tumor 
Steroidal Saponin OSW-1. Tetrahedron Lett. 1998, 39 (10), 1099–1102. 
126. Appendino, G.; Banfi, L. Molecular Diversity and Natural Products. Mol Divers 
2011, 15, 291–292. 
127. Harvey, A. L. Natural Products in Drug Discovery. Drug Discov. Today 2008, 13 
(19–20), 894–901. 
128. Sasidharan, S.; Chen, Y.; Saravanan, D.; Sundram, K. M.; Latha, L. Y.; Bedong-
semeling, J.; Nasi, B. A. Extraction, Isolation and Characterization of Bioactive 
Compounds from Plants Extracts. Afr J Tradit Complement Altern Med 2011, 8 
76 
(1), 1–10. 
129. Amit Koparde, A.; Chandrashekar Doijad, R.; Shripal Magdum, C. Natural 
Products in Drug Discovery. Intech 2019. 
130. Nawaz, H.; Shad, M. A.; Rehman, N.; Andaleeb, H.; Ullah, N. Effect of Solvent 
Polarity on Extraction Yield and Antioxidant Properties of Phytochemicals from 
Bean (Phaseolus Vulgaris) Seeds. Brazilian J. Pharm. Sci. 2020, 56. 
131. Rasul, M. Extraction, Isolation and Characterization of Natural Products from 
Medicinal Plants. Int. J. Basic Sci. Appl. Comput. 2018, 2 (6), 1–6. 
132. Resolution and Peak Separation 
https://www.shimadzu.com/an/hplc/support/lib/lctalk/resol-1.html. 
133. Kasai, Hiroko, F.; Tsubuki, M.; Matsuo, S.; Honda, T. Analysis of Antitumor 
Active OSW-1 and Its Analogues by Liquid Chromatography Coupled with 
Electrospray and Atmospheric Pressure Chemical Ionization Quadrupole Mass 
Spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 1100–1114. 
134. Kasai, H.; Tsubuki, M.; Shimada, K.; Nambara, T.; Honda, T. Analyses of 
Biologically Active Steroids: Antitumor Active OSW-1 and Cardiotonic 
Marinobufotoxin, by Matrix-Assisted Laser Desorption/Ionization Quadrupole Ion 
Trap Time-of-Flight Tandem Mass Spectrometry. Chem. Pharm. Bull. 2009, 57 
(9), 948–956. 
135. Bouslimani, A.; Sanchez, L. M.; Garg, N.; Dorrestein, P. C. Mass Spectrometry of 
Natural Products: Current, Emerging and Future Technologies. Nat. Prod. Rep. 
2014, 31 (6), 718–729. 
136. Merck. LC-MS Contaminants. How to Identify and Avoid Contaminants in LC-
77 
MS. 
137. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for 
Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43 (14), 
2923–2925. 
138. Quinn, R. A.; Nothias, L. F.; Vining, O.; Meehan, M.; Esquenazi, E.; Dorrestein, 
P. C. Molecular Networking As a Drug Discovery, Drug Metabolism, and 
Precision Medicine Strategy. Trends Pharmacol. Sci. 2017, 38 (2), 143–154. 
139. Nothias, L. F.; Nothias-Esposito, M.; Da Silva, R.; Touboul, D.; Costa, J.; Paolini, 
J.; Alexandrov, T.; Litaudon, M.; Dorrestein, P. C. et al. Bioactivity-Based 
Molecular Networking for the Discovery of Drug Leads in Natural Product 




Appendix A. Isolated OSW-1 analogs with Structure A ................................................ 80 
Appendix B. Cytotoxic activities of compounds with Structure A (NT: not tested) ..... 81 
Appendix C. Isolated OSW-1 analogs with Structure B ................................................ 82 
Appendix D. Cytotoxic activities of compounds with Structure B (NT: not tested) ..... 83 
Appendix E. Cytotoxic activities of 15 new isolated OSW-1 analogs by Chen et al. ... 83 
Appendix F. Modified steroidal nucleus analogs 68 and 69 and their cytotoxic activities 
(NT: Not Tested) ............................................................................................................ 84 
Appendix G. Modified side chain analogs 70-101 and their cytotoxic activities (NT: Not 
Tested) ............................................................................................................................ 84 
Appendix H. Modified disaccharide analogs 102-105 and their cytotoxic activities  (NT: 
Not Tested) ..................................................................................................................... 87 
Appendix I. OSW-1 analogs with modified side chains and disaccharide moieties ...... 87 
Appendix J. OSW-1 sulfur-containing analogs identified by HPLC-MS ...................... 87 
Appendix K. Selected Analytical method comparison. Stepped gradient 75/25 to 85/15 to 
100/0 MeOH/H2O (left) and stepped gradient 70/30 to 85/15 to 100/0 MeCN/H2O ..... 88 
Appendix L. Compounds LC-MS data IF-I-27 Fractions F1-4, F5-10 and F11-27 ....... 89 
Appendix M. Compound LC-MS data IF-I-27 Fractions F28-37, F38-60 and F61-69 . 90 
Appendix N. Compound LC-MS data IF-I-27 Fractions F70-72 and Wash .................. 91 
Appendix O. Compound LC-MS data IF-I-29 Fractions F26-37, F38-45, F46-53 and F54-
68 .................................................................................................................................... 92 
Appendix P. NMR Spectrum of 2 (OSW-1) .................................................................. 93 
Appendix Q. NMR Spectrum of 3 (DMBz Analog) ...................................................... 94 
79 
Appendix R. NMR Spectrum of 4 (E-CNM Analog) ..................................................... 95 
Appendix S. NMR Spectrum of 9 (PHBz Analog) ........................................................ 96 
Appendix T. NMR Spectrum of 20 (Cholestane Rhamnoside) ...................................... 97 































Appendix B. Cytotoxic activities of compounds with Structure A (NT: not tested) 
Compounds 
IC50 values (nM) 
HL-60 A549 
1 3.4 ± 0.076 98 ± 8.0 
2 (OSW-1) 0.061 ±0.002 0.65 ± 0.018 
3 0.19 ±0.0026 1.7 ± 005 
4 0.077 ±0.0070 0.68 ±0.057 
5 0.24 NT 
6 0.12 NT 
7 16 NT 
8 14 NT 
9 0.20 ± 0.0074 3.6 ± 0.37 
10 0.55 ± 0.013 6.2 ± 0.10 
11 NT NT 
12 inactive NT 
13 109 NT 
14 2670 ± 310 NT 
15 inactive NT 
16 0.99 NT 
17 inactive NT 
18 7120 ± 270 NT 
19 50 ± 10 270 ± 40 
20 60 ± 2 370 ± 90 
21 inactive NT 
22 inactive NT 
23 1570 ± 100 NT 
24 inactive NT 
25 inactive NT 
26 inactive NT 
27 7720 ± 420 NT 
28 5330 ± 330 NT 
29 5940 ± 100 NT 
30 90 ± 10 2410 ± 170 
31 160 ± 20 1840 ± 310 
32 80 ± 10 980 ± 90 
33 20 (LC50 value, nM) NT 
34 inactive inactive 
35 inactive inactive 
36 inactive inactive 
82 









Appendix D. Cytotoxic activities of compounds with Structure B (NT: not tested) 
Compounds 
IC50 values (nM) 
HL-60 MOLT-4 A549 
37 1,800 1,300 NT 
38 9.2 3.2 NT 
39 inactive inactive NT 
40 inactive inactive NT 
41 21 18 1,010 ± 17 
42 19 NT NT 
43 63 NT 4930 ± 60 
44 52 NT NT 
45 37 ± 4.4 NT 1,030 ± 69 
46 90 ± 14 NT 500 ± 53 
47 inactive inactive NT 
48 790 ± 17 NT 5,790 ± 280 
49 inactive NT inactive 
50 58 ± 2.0 NT 900 ± 11 
51 67 ± 0.23 NT 850 ± 15 
52 170 ± 5.1 NT 5,500 ± 170 
Appendix E. Cytotoxic activities of 15 new isolated OSW-1 analogs by Chen et al.  
New 
Compounds 
IC50 values (nM) 
A549 BGC-823 HCT-116 HepG2 MCF7 
53 inactive inactive inactive inactive inactive 
54 inactive inactive inactive inactive inactive 
55 inactive inactive inactive inactive inactive 
56 inactive inactive inactive inactive inactive 
57 inactive inactive inactive inactive 200 
58 inactive inactive inactive inactive inactive 
59 inactive inactive inactive inactive inactive 
60 inactive inactive inactive inactive inactive 
61 inactive inactive inactive inactive inactive 
62 inactive inactive inactive inactive inactive 
63 inactive inactive inactive inactive inactive 
64 inactive inactive inactive inactive inactive 
65 inactive inactive inactive inactive inactive 
66 inactive inactive inactive inactive inactive 
67 inactive inactive inactive inactive inactive 
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Appendix F. Modified steroidal nucleus analogs 68 and 69 and their cytotoxic 
activities (NT: Not Tested) 
Compounds 
IC50 values (nM) 







A498 PC-3 DLD1 
68 710 25 29 NT NT NT NT NT NT 
69 NT NT NT 439 709 1010 430 1400 1180 





IC50 values (nM) or *TCS50 (10-3 µM) 




70 3.4 4.2 130 NT NT NT 
71 inactive 73 1400 NT NT NT 
72 230 0.68 900 NT NT NT 
73 240 5.3 inactive NT NT NT 
74 3.3 7.3 140 NT NT NT 
75 2 1.4 2600 NT NT NT 
76 inactive inactive inactive NT NT NT 
77 65 2.7 100 NT NT NT 
78 40 3 190 NT NT NT 
79 1.3 0.9 5200 NT NT NT 
80 8.4 5.3 1800 NT NT NT 
81 12 35 inactive NT NT NT 
82 NT NT inactive inactive inactive NT 
83 NT NT inactive inactive inactive NT 
84 NT NT inactive inactive inactive NT 
85 NT NT inactive inactive inactive NT 
86 NT NT 6610 NT NT 6980 
87 *12 NT 20 NT NT 1920 
88 *8 NT *40 NT NT NT 
89 inactive NT inactive NT NT NT 
90 *350 NT *860 NT NT NT 
91 NT NT 60 NT NT 1380 
92 inactive NT inactive NT NT NT 
93 inactive NT inactive NT NT NT 
94 inactive NT inactive NT NT NT 
95 inactive NT inactive NT NT NT 
96 inactive NT inactive NT NT NT 
97 inactive NT inactive NT NT NT 
98 inactive NT inactive NT NT NT 
99 inactive NT inactive NT NT NT 
100 inactive NT inactive NT NT NT 







IC50 values (nM) or *TCS50 (10-3 µM) 
7404 CEM G361 HOS A549 T98 HCT116 BJ 
70 NT NT NT NT NT NT NT NT 
71 NT NT NT NT NT NT NT NT 
72 NT NT NT NT NT NT NT NT 
73 NT NT NT NT NT NT NT NT 
74 NT NT NT NT NT NT NT NT 
75 NT NT NT NT NT NT NT NT 
76 NT NT NT NT NT NT NT NT 
77 NT NT NT NT NT NT NT NT 
78 NT NT NT NT NT NT NT NT 
79 NT NT NT NT NT NT NT NT 
80 NT NT NT NT NT NT NT NT 
81 NT NT NT NT NT NT NT NT 
82 NT NT NT NT NT NT NT NT 
83 NT NT NT NT NT NT NT NT 
84 NT NT NT NT NT NT NT NT 
85 NT NT NT NT NT NT NT NT 
86 2900 NT NT NT NT NT NT NT 
87 32 *0.5 *3100 *140 *0.9 NT NT NT 
88 NT *0.2 *1400 *42 *0.5 NT NT NT 
89 NT *1300 inactive NT NT NT NT NT 
90 NT *<200 *1900 1800 *<200 NT NT NT 
91 63 NT NT NT NT NT NT NT 
92 NT inactive inactive inactive inactive inactive inactive inactive 
93 NT inactive inactive inactive inactive inactive inactive inactive 
94 NT 7200 inactive inactive inactive inactive inactive 7000 
95 NT 6300 8000 inactive inactive 7000 inactive 5000 
96 NT inactive inactive inactive inactive inactive inactive inactive 
97 NT inactive inactive inactive inactive inactive inactive inactive 
98 NT inactive inactive inactive inactive inactive inactive inactive 
99 NT inactive inactive inactive inactive inactive inactive inactive 
100 NT inactive inactive inactive inactive inactive inactive inactive 








Appendix H. Modified disaccharide analogs 102-105 and their cytotoxic activities  
(NT: Not Tested) 
 
Compounds 
TCS50 values (10-3 µM) 
CEM MCF7 K562 ARN8 G361 Hela HOS A549 
102 NT NT NT NT NT NT NT NT 
103 200 1300 430 inactive 2200 570 inactive inactive 
104 NT NT NT NT NT NT NT NT 
105 inactive inactive inactive inactive 3500 inactive inactive inactive 
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Appendix K. Selected Analytical method comparison. Stepped gradient 75/25 to 85/15 
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Appendix R. NMR Spectrum of 4 (E-CNM Analog) 
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Appendix S. NMR Spectrum of 9 (PHBz Analog) 
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Appendix T. NMR Spectrum of 20 (Cholestane Rhamnoside) 
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Appendix U. NMR Spectrum of IF-111 (Novel C24-C25 Unsaturated Analog) 
 
